https://simplecast.com Canadian Urological Association (CUA) The official podcast of the Canadian Urological Association (CUA). Le podcast officiel de l'association des urologues du Canada (AUC). Canadian Urological Association / L'Association des urologues du Canada en Tue, 4 Mar 2025 21:03:21 +0000 Thu, 3 Apr 2025 01:34:55 +0000 https://cua.simplecast.com Canadian Urological Association (CUA) https://image.simplecastcdn.com/images/40e324e4-37cd-499e-8e40-fe60892c64a7/389103f6-e311-44b0-ba7f-29459207a502/3000x3000/cua-crest-logo-2019-final.jpg?aid=rss_feed https://cua.simplecast.com episodic The official podcast of the Canadian Urological Association (CUA). Le podcast officiel de l'association des urologues du Canada (AUC). Canadian Urological Association / L'Association des urologues du Canada false https://feeds.simplecast.com/O8B_xuPb medicine, urologic, urology Canadian Urological Association / L'Association des urologues du Canada corporate.office@cua.org b96a21d0-3724-4a06-8949-3398ef852bdf Canadian Expert discussion on the treatment and management considerations for MIBC treatment regimens Episode Notes

Podcast Host Disclosures:

Dr. Black has received honoraria from AbbVie, Astellas Pharma, AstraZeneca, Bayer, Biosyent, Bristol- Myers Squibb, EMD-Serono, Ferring, Janssen Oncology, Merck, Nanology, Nonagen, Pfizer, Prokarium, Protara, QED, Roche Canada, Sanofi Canada, STIMIT, Urogen Pharma and Verity

Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

]]> Tue, 4 Mar 2025 21:03:21 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/canadian-expert-discussion-on-the-treatment-and-management-considerations-for-mibc-treatment-regimens-AlLDXqJo Episode Notes

Podcast Host Disclosures:

Dr. Black has received honoraria from AbbVie, Astellas Pharma, AstraZeneca, Bayer, Biosyent, Bristol- Myers Squibb, EMD-Serono, Ferring, Janssen Oncology, Merck, Nanology, Nonagen, Pfizer, Prokarium, Protara, QED, Roche Canada, Sanofi Canada, STIMIT, Urogen Pharma and Verity

Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

]]> Canadian Expert discussion on the treatment and management considerations for MIBC treatment regimens Canadian Urological Association / L'Association des urologues du Canada 00:30:20 In this podcast, Dr. Aly-Khan Lalani and Dr. Peter Black discuss the latest advancements in treatment for patients with muscle-invasive bladder cancer, the clinical efficacy of newly available treatment options in Canada, and treatment selection and management considerations for treatment regimens in Canada. In this podcast, Dr. Aly-Khan Lalani and Dr. Peter Black discuss the latest advancements in treatment for patients with muscle-invasive bladder cancer, the clinical efficacy of newly available treatment options in Canada, and treatment selection and management considerations for treatment regimens in Canada. false full 61 e336f0ab-c2b8-45f7-96e9-65adb1649c82 Canadian Expert discussion on optimizing RCC treatment Episode Notes

Podcast Host Disclosures:

Dr. Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria from: Alkermes, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work. Institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA. Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura. Committees: NCCN, GU Steering Committee, ASCO/ESMO, ACCRU, KidneyCan. Medical writing and editorial assistance support may have been funded by Communications companies in part. No speaker’s bureau. Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T. K. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI. 

Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

]]> Wed, 29 Nov 2023 19:14:39 +0000 corporate.office@cua.org (Toni Choueiri, Aly-Khan Lalani) https://cua.simplecast.com/episodes/canadian-expert-discussion-on-optimizing-rcc-treatment-ouRhSkuU Episode Notes

Podcast Host Disclosures:

Dr. Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria from: Alkermes, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work. Institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA. Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura. Committees: NCCN, GU Steering Committee, ASCO/ESMO, ACCRU, KidneyCan. Medical writing and editorial assistance support may have been funded by Communications companies in part. No speaker’s bureau. Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T. K. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI. 

Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

]]> Canadian Expert discussion on optimizing RCC treatment Toni Choueiri, Aly-Khan Lalani 00:42:13 In this podcast, Dr. Aly-Khan Lalani and Dr. Toni Choueiri reflect on the latest advancements in systemic therapy for patients with RCC, summarize the clinical efficacy of newly available IO/TKI treatment options for Canadian patients with RCC. They also discuss treatment selection and management considerations for IO/TKI treatment regimens in the Canadian context. In this podcast, Dr. Aly-Khan Lalani and Dr. Toni Choueiri reflect on the latest advancements in systemic therapy for patients with RCC, summarize the clinical efficacy of newly available IO/TKI treatment options for Canadian patients with RCC. They also discuss treatment selection and management considerations for IO/TKI treatment regimens in the Canadian context. rcc, renal cell carcinoma, rcc treatment, cua, kidney cancer research, kidney cancer, io/tki treatment options false full 60 9ac416fb-f59b-4dc3-a66d-b45c385b010c 2 Pees In A Pod Podcast - Ep 4 - Introduction to bladder cancer The fourth episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features an introductory discussion on bladder cancer.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

Bladder Cancer Canada

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

]]> Thu, 19 Oct 2023 13:09:39 +0000 corporate.office@cua.org (Claudia Chavez-Munoz, Alan So) https://cua.simplecast.com/episodes/2-pees-in-a-pod-podcast-ep-4-introduction-to-bladder-cancer-PfL9Nvf_ The fourth episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features an introductory discussion on bladder cancer.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

Bladder Cancer Canada

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

]]> 2 Pees In A Pod Podcast - Ep 4 - Introduction to bladder cancer Claudia Chavez-Munoz, Alan So 00:22:44 The fourth episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features an introductory discussion on bladder cancer. The fourth episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features an introductory discussion on bladder cancer. bladder cancer, cua, urology false full 59 49ae029a-9c07-41cc-bf16-19c5e9ac04e2 2 Pees In A Pod Podcast - Ep 3 - Urinary tract infections in women The third episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on urinary tract infections in women.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

]]> Wed, 11 Oct 2023 19:17:42 +0000 corporate.office@cua.org (Claudia Chavez-Munoz, Alan So) https://cua.simplecast.com/episodes/2-pees-in-a-pod-podcast-ep-3-urinary-tract-infections-in-women-RR0gYl_n The third episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on urinary tract infections in women.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

]]> 2 Pees In A Pod Podcast - Ep 3 - Urinary tract infections in women Claudia Chavez-Munoz, Alan So 00:24:07 The third episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on urinary tract infections in women. The third episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on urinary tract infections in women. uti, urinary tract infection, cua, urology false full 58 91558d13-5df2-49c7-a9bf-d1d45c1eab0f 2 Pees In A Pod Podcast - Ep 2 - Male voiding disorders and Benign Prostatic Hyperplasia (BPH) The second episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on male voiding disorders and Benign Prostatic Hyperplasia (BPH).

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

CUA BPH Guidelines - Google Search

Welcome to Canadian Urological Association | Canadian Urological Association (cua.org)

 

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

]]> Wed, 4 Oct 2023 18:41:56 +0000 corporate.office@cua.org (Alan So, Claudia Chavez-Munoz) https://cua.simplecast.com/episodes/2-pees-in-a-pod-podcast-ep-2-male-voiding-disorders-and-benign-prostatic-hyperplasia-bph-7dej1c1m The second episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on male voiding disorders and Benign Prostatic Hyperplasia (BPH).

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

CUA BPH Guidelines - Google Search

Welcome to Canadian Urological Association | Canadian Urological Association (cua.org)

 

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

]]> 2 Pees In A Pod Podcast - Ep 2 - Male voiding disorders and Benign Prostatic Hyperplasia (BPH) Alan So, Claudia Chavez-Munoz 00:32:19 The second episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on male voiding disorders and Benign Prostatic Hyperplasia (BPH). The second episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on male voiding disorders and Benign Prostatic Hyperplasia (BPH). cua, urology, bph, female voiding disorders false full 57 821afb57-7151-481a-9112-79505864b0df 2 Pees In A Pod Podcast - Ep 1 - PSA and Prostate Cancer Screening Our inaugural 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz! This first podcast in the series focuses on PSA and Prostate Cancer Screening.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis - PMC (nih.gov)

UBC & VGH Centre of Excellence | Vancouver Prostate Centre

Welcome to Canadian Urological Association | Canadian Urological Association (cua.org)

 

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

]]> Wed, 27 Sep 2023 18:47:29 +0000 corporate.office@cua.org (Alan So, Claudia Chavez-Munoz) https://cua.simplecast.com/episodes/2-pees-in-a-pod-podcast-psa-and-prostate-cancer-screening-Dt1BzX6O Our inaugural 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz! This first podcast in the series focuses on PSA and Prostate Cancer Screening.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis - PMC (nih.gov)

UBC & VGH Centre of Excellence | Vancouver Prostate Centre

Welcome to Canadian Urological Association | Canadian Urological Association (cua.org)

 

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

]]> 2 Pees In A Pod Podcast - Ep 1 - PSA and Prostate Cancer Screening Alan So, Claudia Chavez-Munoz 00:28:57 Our inaugural 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz! This first podcast in the series focuses on PSA and Prostate Cancer Screening. Our inaugural 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz! This first podcast in the series focuses on PSA and Prostate Cancer Screening. prostate cancer, prostate cancer screening, psa, cua, urology false full 56 623e2b05-540c-4afb-b4f8-45593cd6c207 CUA Highlights of ESMO 2022 - Kidney Cancer Session - French Program Chair: Ricardo Rendon

Kidney Cancer Panelists: Melissa Huynh, Lori Wood

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> Sat, 1 Oct 2022 16:25:00 +0000 corporate.office@cua.org (Melissa Huynh, Lori Wood) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2022-kidney-cancer-session-french-A_47aBvw Program Chair: Ricardo Rendon

Kidney Cancer Panelists: Melissa Huynh, Lori Wood

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> CUA Highlights of ESMO 2022 - Kidney Cancer Session - French Melissa Huynh, Lori Wood 00:43:48 CUA Highlights of ESMO 2022 - Kidney Cancer Session - French CUA Highlights of ESMO 2022 - Kidney Cancer Session - French esmo, cua, esmo 2022, kidney cancer false full 55 28428001-39f1-4ea8-868b-ce4f1649a80e CUA Highlights of ESMO 2022 - Kidney Cancer Session - English Program Chair: Ricardo Rendon

Kidney Cancer Panelists: Melissa Huynh, Lori Wood

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> Sat, 1 Oct 2022 16:20:00 +0000 corporate.office@cua.org (Melissa Huynh, Lori Wood) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2022-kidney-cancer-session-english-GDZe_6U_ Program Chair: Ricardo Rendon

Kidney Cancer Panelists: Melissa Huynh, Lori Wood

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> CUA Highlights of ESMO 2022 - Kidney Cancer Session - English Melissa Huynh, Lori Wood 00:43:50 CUA Highlights of ESMO 2022 - Kidney Cancer Session - English CUA Highlights of ESMO 2022 - Kidney Cancer Session - English esmo, cua, esmo 2022, kidney cancer false full 54 60a57668-c40c-4b42-878f-95a9018439cf CUA Highlights of ESMO 2022 - Bladder Cancer Session - French Program Chair: Ricardo Rendon

Bladder Cancer Panelists: Peter Black, Maria Jiang

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> Sat, 1 Oct 2022 16:15:00 +0000 corporate.office@cua.org (Ricardo Rendon, Di (Maria) Jiang, Peter Black) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2022-bladder-cancer-session-french-3fIkto6V Program Chair: Ricardo Rendon

Bladder Cancer Panelists: Peter Black, Maria Jiang

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> CUA Highlights of ESMO 2022 - Bladder Cancer Session - French Ricardo Rendon, Di (Maria) Jiang, Peter Black 00:41:08 CUA Highlights of ESMO 2022 - Bladder Cancer Session - French CUA Highlights of ESMO 2022 - Bladder Cancer Session - French esmo, bladder cancer, cua, esmo 2022 false full 53 88414845-fe48-4912-a8a2-9da1646d8a34 CUA Highlights of ESMO 2022 - Bladder Cancer Session - English Program Chair: Ricardo Rendon

Bladder Cancer Panelists: Peter Black, Maria Jiang

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> Sat, 1 Oct 2022 16:10:00 +0000 corporate.office@cua.org (Peter Black, Ricardo Rendon, Di (Maria) Jiang) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2022-bladder-cancer-session-english-CImn4PBW Program Chair: Ricardo Rendon

Bladder Cancer Panelists: Peter Black, Maria Jiang

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> CUA Highlights of ESMO 2022 - Bladder Cancer Session - English Peter Black, Ricardo Rendon, Di (Maria) Jiang 00:41:47 CUA Highlights of ESMO 2022 - Bladder Cancer Session - English CUA Highlights of ESMO 2022 - Bladder Cancer Session - English esmo, bladder cancer, cua, esmo 2022 false full 52 9c168aab-97bd-435d-946c-d38bc0b7ead2 CUA Highlights of ESMO 2022 - Prostate Cancer Session - French Program Chair: Ricardo Rendon

Prostate Cancer Panelists: Ricardo Rendon, Sebastien Hotte, Scott Morgan

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> Sat, 1 Oct 2022 16:05:00 +0000 corporate.office@cua.org (Ricardo Rendon, Scott Morgan, Sebastien J. Hotte) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2022-prostate-cancer-session-french-U_2gjr9Y Program Chair: Ricardo Rendon

Prostate Cancer Panelists: Ricardo Rendon, Sebastien Hotte, Scott Morgan

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> CUA Highlights of ESMO 2022 - Prostate Cancer Session - French Ricardo Rendon, Scott Morgan, Sebastien J. Hotte 00:44:45 CUA Highlights of ESMO 2022 - Prostate Cancer Session - French CUA Highlights of ESMO 2022 - Prostate Cancer Session - French prostate cancer, esmo, cua, esmo 2022 false full 51 446257fb-ef4f-4d1d-9ed9-f03d4ce6e9ab CUA Highlights of ESMO 2022 - Prostate Cancer Session - English Program Chair: Ricardo Rendon

Prostate Cancer Panelists: Ricardo Rendon, Sebastien Hotte, Scott Morgan

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> Sat, 1 Oct 2022 16:00:00 +0000 corporate.office@cua.org (Scott Morgan, Ricardo Rendon, Sebastien J. Hotte) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2022-prostate-cancer-session-english-JACwWz_o Program Chair: Ricardo Rendon

Prostate Cancer Panelists: Ricardo Rendon, Sebastien Hotte, Scott Morgan

 

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

]]> CUA Highlights of ESMO 2022 - Prostate Cancer Session - English Scott Morgan, Ricardo Rendon, Sebastien J. Hotte 00:44:44 CUA Highlights of ESMO 2022 - Prostate Cancer Session - English CUA Highlights of ESMO 2022 - Prostate Cancer Session - English prostate cancer, esmo, cua, esmo 2022 true full 50 990c3887-a374-43f8-b6e4-ea44f26b9fd0 Jean Gregoire | CV Risk | Q&A Series Jean Gregoire, MD, FRCP(C), FCCS, FACC, FACP
University of Montreal
Institut de cardiologie de Montreal

]]> Thu, 21 Apr 2022 04:00:00 +0000 corporate.office@cua.org (Jean Gregoire) https://cua.simplecast.com/episodes/cua-q-a-series-cv-risk-jean-gregoire-EkcQ60su Jean Gregoire, MD, FRCP(C), FCCS, FACC, FACP
University of Montreal
Institut de cardiologie de Montreal

]]> Jean Gregoire | CV Risk | Q&A Series Jean Gregoire 00:05:28 Jean Gregoire | CV Risk | Q&A Series Jean Gregoire | CV Risk | Q&A Series urology false full 46 08bfcfa9-020b-4d9e-9379-5c85d841db08 Fred Saad | CV Risk | Q&A Series Fred Saad, MD, FRCS
CHUM, Institut de cancer de Montreal/CRCHUM

]]> Thu, 21 Apr 2022 04:00:00 +0000 corporate.office@cua.org (Fred Saad) https://cua.simplecast.com/episodes/cua-q-a-series-cv-risk-fred-saad-cusz0puf Fred Saad, MD, FRCS
CHUM, Institut de cancer de Montreal/CRCHUM

]]> Fred Saad | CV Risk | Q&A Series Fred Saad 00:05:21 Fred Saad | CV Risk | Q&A Series Fred Saad | CV Risk | Q&A Series urology false full 45 dbf57d04-0246-4b28-aa2e-99d5e5356220 Fred Saad | CV Risk | Q&A Series - French Fred Saad, MD, FRCS
CHUM, Institut de cancer de Montreal/CRCHUM

]]> Thu, 21 Apr 2022 04:00:00 +0000 corporate.office@cua.org (Fred Saad) https://cua.simplecast.com/episodes/fred-saad-cv-risk-qa-series-french-uIFJtrk6 Fred Saad, MD, FRCS
CHUM, Institut de cancer de Montreal/CRCHUM

]]> Fred Saad | CV Risk | Q&A Series - French Fred Saad 00:04:44 Fred Saad | CV Risk | Q&A Series - French Fred Saad | CV Risk | Q&A Series - French q&a, cv risk false full 49 5e9df7ff-f37b-4860-af6e-0a835cb0eb5d Jean Gregoire | CV Risk | Q&A Series - French Jean Gregoire, MD, FRCP(C), FCCS, FACC, FACP
University of Montreal
Institut de cardiologie de Montreal

]]> Thu, 21 Apr 2022 04:00:00 +0000 corporate.office@cua.org (Jean Gregoire) https://cua.simplecast.com/episodes/jean-gregoire-cv-risk-qa-series-french-OegnQ_bm Jean Gregoire, MD, FRCP(C), FCCS, FACC, FACP
University of Montreal
Institut de cardiologie de Montreal

]]> Jean Gregoire | CV Risk | Q&A Series - French Jean Gregoire 00:04:35 Jean Gregoire | CV Risk | Q&A Series - French Jean Gregoire | CV Risk | Q&A Series - French q&a, cv risk false full 48 42df5b58-0394-4997-90a6-cac817d77d55 Darryl Leong | CV Risk | Q&A Series Darryl Leong, MD
McMaster University

]]> Thu, 21 Apr 2022 04:00:00 +0000 corporate.office@cua.org (Darryl Leong) https://cua.simplecast.com/episodes/cua-q-a-series-cv-risk-darryl-leong-lHryqZr0 Darryl Leong, MD
McMaster University

]]> Darryl Leong | CV Risk | Q&A Series Darryl Leong 00:12:19 Darryl Leong | CV Risk | Q&A Series Darryl Leong | CV Risk | Q&A Series urology false full 47 77db1b8c-4577-4398-b9f3-210875ddb1e1 Luke Lavallee | Bone Health Management in Prostate Cancer | Q&A Series Sponsored by Amgen.

Luke Lavallee
Urologic Oncologist and Associate Scientist
The Ottawa Hospital
Ottawa Hospital Research Institute

Disclosures:
Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas
Grant/Honorarium: Sanofi

]]> Wed, 20 Apr 2022 20:18:00 +0000 corporate.office@cua.org (Luke Lavallee) https://cua.simplecast.com/episodes/cua-q-a-series-bone-health-management-in-prostate-cancer-luke-lavallee-J7ffkA2z Sponsored by Amgen.

Luke Lavallee
Urologic Oncologist and Associate Scientist
The Ottawa Hospital
Ottawa Hospital Research Institute

Disclosures:
Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas
Grant/Honorarium: Sanofi

]]> Luke Lavallee | Bone Health Management in Prostate Cancer | Q&A Series Luke Lavallee 00:07:13 Luke Lavallee | Bone Health Management in Prostate Cancer | Q&A Series Luke Lavallee | Bone Health Management in Prostate Cancer | Q&A Series urology false full 44 4d9543bb-1a70-42ac-9ccc-b2ae7b3322cc Sophie Mottard | Bone Health Management in Prostate Cancer | Q&A Series Sponsored by Amgen.

Sophie Mottard
Orthopedic Oncology Surgeon
Maisonneuve-Rosemont Hospital
CHU Saint-Justine and Santa Cabrini Hospital

Disclosures:
Payment: Amgen (conference speaker)

]]> Wed, 20 Apr 2022 20:14:00 +0000 corporate.office@cua.org (Sophie Mottard) https://cua.simplecast.com/episodes/cua-q-a-series-bone-health-management-in-prostate-cancer-sophie-mottard-A1_7AzUR Sponsored by Amgen.

Sophie Mottard
Orthopedic Oncology Surgeon
Maisonneuve-Rosemont Hospital
CHU Saint-Justine and Santa Cabrini Hospital

Disclosures:
Payment: Amgen (conference speaker)

]]> Sophie Mottard | Bone Health Management in Prostate Cancer | Q&A Series Sophie Mottard 00:20:14 Sophie Mottard | Bone Health Management in Prostate Cancer | Q&A Series Sophie Mottard | Bone Health Management in Prostate Cancer | Q&A Series urology false full 43 d285e2ca-791f-403d-95ef-a0518b27657d David Kendler | Bone Health Management in Prostate Cancer | Q&A Series Sponsored by Amgen.

David Kendler
Endocrinologist and Clinical Professor
UBC

Disclosures:
Advisory Board: Amgen, Paladin, Biosynt
Speakers Bureau: Amgen
Payment: Amgen, Biosynt, Radius Pharma, Paladin
Grant/Honorarium: Amgen, Biosynt, Radius Pharma, Paladin
Clinical Trial: Radius Pharma
Leadership/Board Position: Specialists of BC, Drs. of BC section of Endocrinology (executive)

 

]]> Wed, 20 Apr 2022 04:15:00 +0000 corporate.office@cua.org (David Kendler) https://cua.simplecast.com/episodes/cua-q-a-series-bone-health-management-in-prostate-cancer-david-kendler-uJoE_gM4 Sponsored by Amgen.

David Kendler
Endocrinologist and Clinical Professor
UBC

Disclosures:
Advisory Board: Amgen, Paladin, Biosynt
Speakers Bureau: Amgen
Payment: Amgen, Biosynt, Radius Pharma, Paladin
Grant/Honorarium: Amgen, Biosynt, Radius Pharma, Paladin
Clinical Trial: Radius Pharma
Leadership/Board Position: Specialists of BC, Drs. of BC section of Endocrinology (executive)

 

]]> David Kendler | Bone Health Management in Prostate Cancer | Q&A Series David Kendler 00:15:21 David Kendler | Bone Health Management in Prostate Cancer | Q&A Series David Kendler | Bone Health Management in Prostate Cancer | Q&A Series urology false full 42 946cf0f2-13e0-4f19-8f29-3bf88bee85c1 Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones Disclosures:

Hassan Razvi
Patent: Cook Urological
Clinical Trials: Boston Scientific, Verity Pharma
Leadership/board position: AUA, Endourology Society

Olivier Traxer
Consultant: Karl Storz, Coloplast, IPG Medical, ROCAMED, Boston Scientific, Quanta, AMBU

]]> Wed, 20 Apr 2022 04:00:00 +0000 corporate.office@cua.org (Olivier Traxer, Hassan Razvi) https://cua.simplecast.com/episodes/why-the-tm-fibre-laser-is-superior-to-the-ho-yag-for-urinary-stones-agDea0Xy Disclosures:

Hassan Razvi
Patent: Cook Urological
Clinical Trials: Boston Scientific, Verity Pharma
Leadership/board position: AUA, Endourology Society

Olivier Traxer
Consultant: Karl Storz, Coloplast, IPG Medical, ROCAMED, Boston Scientific, Quanta, AMBU

]]> Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones Olivier Traxer, Hassan Razvi 01:07:39 Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones laser, tm:fibre, ho:yag, urinary stones false full 40 0883ea5a-fcb3-4c18-94df-e9713226156f Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones - French Disclosures:

Hassan Razvi
Patent: Cook Urological
Clinical Trials: Boston Scientific, Verity Pharma
Leadership/board position: AUA, Endourology Society

Olivier Traxer
Consultant: Karl Storz, Coloplast, IPG Medical, ROCAMED, Boston Scientific, Quanta, AMBU

 

]]> Wed, 20 Apr 2022 04:00:00 +0000 corporate.office@cua.org (Hassan Razvi, Olivier Traxer) https://cua.simplecast.com/episodes/why-the-tm-fibre-laser-is-superior-to-the-ho-yag-for-urinary-stones-french-nU4RFs8w Disclosures:

Hassan Razvi
Patent: Cook Urological
Clinical Trials: Boston Scientific, Verity Pharma
Leadership/board position: AUA, Endourology Society

Olivier Traxer
Consultant: Karl Storz, Coloplast, IPG Medical, ROCAMED, Boston Scientific, Quanta, AMBU

 

]]> Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones - French Hassan Razvi, Olivier Traxer 01:07:38 Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones - French Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones - French laser, tm:fibre, ho:yag, urinary stones false full 41 b9a47915-af54-45d5-a53d-0a0ef0ed4b92 CUA Highlights of GU ASCO 2022 - Bladder Cancer Session - French Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Nimira Alimohamed
Advisory Board/Consultancy roles: Pfizer, EMD Serono, Merck, Seagen

Wassim Kassouf
No disclosures

Alejandro Berlin
No disclosures

]]> Tue, 22 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Anil Kapoor, Nimira Alimohamed, Wassim Kassouf, Alejandro Berlin) https://cua.simplecast.com/episodes/cua-highlights-of-gu-asco-2022-bladder-cancer-session-french-73f4bKZx Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Nimira Alimohamed
Advisory Board/Consultancy roles: Pfizer, EMD Serono, Merck, Seagen

Wassim Kassouf
No disclosures

Alejandro Berlin
No disclosures

]]> CUA Highlights of GU ASCO 2022 - Bladder Cancer Session - French Anil Kapoor, Nimira Alimohamed, Wassim Kassouf, Alejandro Berlin 00:42:37 CUA Highlights of GU ASCO 2022 - Bladder Cancer Session - French CUA Highlights of GU ASCO 2022 - Bladder Cancer Session - French gu asco 2022, bladder cancer false full 38 466fee0f-2b67-4ec8-9c5b-e2375eabd6c0 CUA Highlights of GU ASCO 2022 - Kidney Cancer Session - French Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Christian Kollmannsberger
Consultant: Pfizer, Merck, Sanofi, Astellas, BMS, Ipsen, Eisai, Bayer
Honoraria for presentations: Pfizer, Ipsen, Eisai, BMS, Janssen, Bayer
Scientific Advisory Board: Pfizer, Novartis, Ipsen, Eisai, Sanofi, Astellas, BMS, Janssen, Bayer, Merck

]]> Tue, 22 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Anil Kapoor, Christian Kollmannsberger, W. Chu) https://cua.simplecast.com/episodes/cua-highlights-of-gu-asco-2022-kidney-cancer-session-french-mkHcpoA5 Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Christian Kollmannsberger
Consultant: Pfizer, Merck, Sanofi, Astellas, BMS, Ipsen, Eisai, Bayer
Honoraria for presentations: Pfizer, Ipsen, Eisai, BMS, Janssen, Bayer
Scientific Advisory Board: Pfizer, Novartis, Ipsen, Eisai, Sanofi, Astellas, BMS, Janssen, Bayer, Merck

]]> CUA Highlights of GU ASCO 2022 - Kidney Cancer Session - French Anil Kapoor, Christian Kollmannsberger, W. Chu 00:49:26 CUA Highlights of GU ASCO 2022 - Kidney Cancer Session - French CUA Highlights of GU ASCO 2022 - Kidney Cancer Session - French gu asco 2022, kidney cancer false full 39 973f37f5-bd8c-4a0f-8ad4-e26721066137 CUA Highlights of GU ASCO 2022 - Prostate Cancer Session - French Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Tamim Niazi
Honoraria/ research funding: Abbvie, Astellas, Bayer, Janssen, Sanofi, Merck, AstraZeneca, TerSera, Knight Therapeutics, Amgen, Tolmar, Sanofi, Ferring

Krista Noonan
Consultancy-Astellas, AstraZeneca, EMD Serono, Janssen, Pfizer

 

Ricardo Rendon

Advisory Board: Astellas, Amgen, Abbvie, AstraZeneca, Bayer, Ferring, Janssen, Sanofi, TerSera

Speakers' Bureau: Amgen, Astellas, Bayer, Ferring, Janssen,

Grant/Honorarium: Astellas, Amgen, Bayer Janssen

Clinical Trial: Abbvie, Amgen, Astellas, AstraZeneca, Ferring, Janssen, Pfizer, Sanofi, Myovant

]]> Tue, 22 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Anil Kapoor, Tamim Niazi, Krista Noonan, Ricardo Rendon) https://cua.simplecast.com/episodes/cua-highlights-of-gu-asco-2022-prostate-cancer-session-french-zWdjRp7N Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Tamim Niazi
Honoraria/ research funding: Abbvie, Astellas, Bayer, Janssen, Sanofi, Merck, AstraZeneca, TerSera, Knight Therapeutics, Amgen, Tolmar, Sanofi, Ferring

Krista Noonan
Consultancy-Astellas, AstraZeneca, EMD Serono, Janssen, Pfizer

 

Ricardo Rendon

Advisory Board: Astellas, Amgen, Abbvie, AstraZeneca, Bayer, Ferring, Janssen, Sanofi, TerSera

Speakers' Bureau: Amgen, Astellas, Bayer, Ferring, Janssen,

Grant/Honorarium: Astellas, Amgen, Bayer Janssen

Clinical Trial: Abbvie, Amgen, Astellas, AstraZeneca, Ferring, Janssen, Pfizer, Sanofi, Myovant

]]> CUA Highlights of GU ASCO 2022 - Prostate Cancer Session - French Anil Kapoor, Tamim Niazi, Krista Noonan, Ricardo Rendon 00:47:07 CUA Highlights of GU ASCO 2022 - Prostate Cancer Session - French CUA Highlights of GU ASCO 2022 - Prostate Cancer Session - French prostate cancer, gu asco 2022 false full 37 6291e731-49e0-454b-bac8-8ba6eb23db8b CUA Highlights of GU ASCO 2022 - Kidney Cancer Session Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Christian Kollmannsberger
Consultant: Pfizer, Merck, Sanofi, Astellas, BMS, Ipsen, Eisai, Bayer
Honoraria for presentations: Pfizer, Ipsen, Eisai, BMS, Janssen, Bayer
Scientific Advisory Board: Pfizer, Novartis, Ipsen, Eisai, Sanofi, Astellas, BMS, Janssen, Bayer, Merck

]]> Tue, 22 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Anil Kapoor, Christian Kollmannsberger, W. Chu) https://cua.simplecast.com/episodes/cua-highlights-of-gu-asco-2022-kidney-cancer-session-s6zHiwFM Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Christian Kollmannsberger
Consultant: Pfizer, Merck, Sanofi, Astellas, BMS, Ipsen, Eisai, Bayer
Honoraria for presentations: Pfizer, Ipsen, Eisai, BMS, Janssen, Bayer
Scientific Advisory Board: Pfizer, Novartis, Ipsen, Eisai, Sanofi, Astellas, BMS, Janssen, Bayer, Merck

]]> CUA Highlights of GU ASCO 2022 - Kidney Cancer Session Anil Kapoor, Christian Kollmannsberger, W. Chu 00:49:27 CUA Highlights of GU ASCO 2022 - Kidney Cancer Session CUA Highlights of GU ASCO 2022 - Kidney Cancer Session gu asco 2022, kidney cancer false full 36 5283cb1f-c674-4375-94d5-b1ebb7d98e1e CUA Highlights of GU ASCO 2022 - Bladder Cancer Session Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Nimira Alimohamed
Advisory Board/Consultancy roles: Pfizer, EMD Serono, Merck, Seagen

Wassim Kassouf
No disclosures

Alejandro Berlin
No disclosures

]]> Tue, 22 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Anil Kapoor, Nimira Alimohamed, Wassim Kassouf, Alejandro Berlin) https://cua.simplecast.com/episodes/cua-highlights-of-gu-asco-2022-bladder-cancer-session-GqaYpM0f Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Nimira Alimohamed
Advisory Board/Consultancy roles: Pfizer, EMD Serono, Merck, Seagen

Wassim Kassouf
No disclosures

Alejandro Berlin
No disclosures

]]> CUA Highlights of GU ASCO 2022 - Bladder Cancer Session Anil Kapoor, Nimira Alimohamed, Wassim Kassouf, Alejandro Berlin 00:42:37 CUA Highlights of GU ASCO 2022 - Bladder Cancer Session CUA Highlights of GU ASCO 2022 - Bladder Cancer Session gu asco 2022, bladder cancer false full 35 a469eef4-74c5-4805-9d29-e0899c6a4859 CUA Highlights of GU ASCO 2022 - Prostate Cancer Session Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Tamim Niazi
Honoraria/ research funding: Abbvie, Astellas, Bayer, Janssen, Sanofi, Merck, AstraZeneca, TerSera, Knight Therapeutics, Amgen, Tolmar, Sanofi, Ferring

Krista Noonan
Consultancy-Astellas, AstraZeneca, EMD Serono, Janssen, Pfizer

Ricardo Rendon
Advisory Board: Astellas, Amgen, Abbvie, AstraZeneca, Bayer, Ferring, Janssen, Sanofi, TerSera
Speakers' Bureau: Amgen, Astellas, Bayer, Ferring, Janssen,
Grant/Honorarium: Astellas, Amgen, Bayer Janssen
Clinical Trial: Abbvie, Amgen, Astellas, AstraZeneca, Ferring, Janssen, Pfizer, Sanofi, Myovant

]]> Tue, 22 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Anil Kapoor, Tamim Niazi, Krista Noonan, Ricardo Rendon) https://cua.simplecast.com/episodes/cua-highlights-of-gu-asco-2022-prostate-cancer-session-AvPbU7Ro Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Tamim Niazi
Honoraria/ research funding: Abbvie, Astellas, Bayer, Janssen, Sanofi, Merck, AstraZeneca, TerSera, Knight Therapeutics, Amgen, Tolmar, Sanofi, Ferring

Krista Noonan
Consultancy-Astellas, AstraZeneca, EMD Serono, Janssen, Pfizer

Ricardo Rendon
Advisory Board: Astellas, Amgen, Abbvie, AstraZeneca, Bayer, Ferring, Janssen, Sanofi, TerSera
Speakers' Bureau: Amgen, Astellas, Bayer, Ferring, Janssen,
Grant/Honorarium: Astellas, Amgen, Bayer Janssen
Clinical Trial: Abbvie, Amgen, Astellas, AstraZeneca, Ferring, Janssen, Pfizer, Sanofi, Myovant

]]> CUA Highlights of GU ASCO 2022 - Prostate Cancer Session Anil Kapoor, Tamim Niazi, Krista Noonan, Ricardo Rendon 00:47:07 CUA Highlights of GU ASCO 2022 - Prostate Cancer Session CUA Highlights of GU ASCO 2022 - Prostate Cancer Session prostate cancer, gu asco 2022 false full 34 e5cbbd72-57b7-449d-99a8-c09f679a6d1d CUA Practice Changing Publications (PCP) - Endourology (Surgical Management of BPH) Disclosures:

Dean Elterman
Advisory Boards/ Speakers Bureaus: Astellas, Boston Scientific, Duchesnay, Pfizer, Procept, Prodeon, Olympus, Medtronic, Urotronic, Zeneflow

Kevin Zorn
Advisory Board: BSCI, Procept, Zenflow

]]> Tue, 15 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Dean Elterman, Kevin Zorn) https://cua.simplecast.com/episodes/cua-practice-changing-publications-pcp-endourology-surgical-management-of-bph-BvnQm6Eg Disclosures:

Dean Elterman
Advisory Boards/ Speakers Bureaus: Astellas, Boston Scientific, Duchesnay, Pfizer, Procept, Prodeon, Olympus, Medtronic, Urotronic, Zeneflow

Kevin Zorn
Advisory Board: BSCI, Procept, Zenflow

]]> CUA Practice Changing Publications (PCP) - Endourology (Surgical Management of BPH) Dean Elterman, Kevin Zorn 00:58:12 CUA Practice Changing Publications (PCP) - Endourology (Surgical Management of BPH) CUA Practice Changing Publications (PCP) - Endourology (Surgical Management of BPH) bph, pcp, surgical management, endourology false full 33 173153d6-061e-42c4-b6e9-024607e7b0f0 V2P2 2022 - An Update in Advanced Prostate Cancer - French Disclosures:

Fred Saad
Grants/Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi

Eleni Efstathiou
Research Support/P.I.: Janssen, Sanofi-Genzyme, Astellas/Medivation, Oric-Pharma, Nuvation
Scientific Advisory Board/Honoraria: Janssen, Sanofi-Genzyme, Bayer, Oric Pharma, Marck, AAA-Novartis, Genetech, Astra-Zeneca, Astellas, Pfizer, Myovant 

]]> Thu, 10 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Fred Saad, Eleni Efstathiou) https://cua.simplecast.com/episodes/v2p2-2022-an-update-in-advanced-prostate-cancer-french-yEr0536F Disclosures:

Fred Saad
Grants/Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi

Eleni Efstathiou
Research Support/P.I.: Janssen, Sanofi-Genzyme, Astellas/Medivation, Oric-Pharma, Nuvation
Scientific Advisory Board/Honoraria: Janssen, Sanofi-Genzyme, Bayer, Oric Pharma, Marck, AAA-Novartis, Genetech, Astra-Zeneca, Astellas, Pfizer, Myovant 

]]> V2P2 2022 - An Update in Advanced Prostate Cancer - French Fred Saad, Eleni Efstathiou 01:01:18 V2P2 2022 - An Update in Advanced Prostate Cancer - French V2P2 2022 - An Update in Advanced Prostate Cancer - French advanced prostate cancer, v2p2 2022 false full 32 c55f0e10-716e-43ab-8990-6c3d81fd5c63 V2P2 2022 - An Update in Advanced Prostate Cancer Disclosures:

Fred Saad
Grants/Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi

Eleni Efstathiou
Research Support/P.I.: Janssen, Sanofi-Genzyme, Astellas/Medivation, Oric-Pharma, Nuvation
Scientific Advisory Board/Honoraria: Janssen, Sanofi-Genzyme, Bayer, Oric Pharma, Marck, AAA-Novartis, Genetech, Astra-Zeneca, Astellas, Pfizer, Myovant

]]> Thu, 10 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Fred Saad, Eleni Efstathiou) https://cua.simplecast.com/episodes/v2p2-2022-an-update-in-advanced-prostate-cancer-8yv3JrSn Disclosures:

Fred Saad
Grants/Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi

Eleni Efstathiou
Research Support/P.I.: Janssen, Sanofi-Genzyme, Astellas/Medivation, Oric-Pharma, Nuvation
Scientific Advisory Board/Honoraria: Janssen, Sanofi-Genzyme, Bayer, Oric Pharma, Marck, AAA-Novartis, Genetech, Astra-Zeneca, Astellas, Pfizer, Myovant

]]> V2P2 2022 - An Update in Advanced Prostate Cancer Fred Saad, Eleni Efstathiou 01:01:18 V2P2 2022 - An Update in Advanced Prostate Cancer V2P2 2022 - An Update in Advanced Prostate Cancer prostate cancer, v2p2 2022 false full 31 0b9538b8-2afe-4ae4-a259-b7834f41df5a Practice Changing Publications (PCP): Update in Kidney Cancer Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position: Kidney Cancer Canada

Luke Lavallee
Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas
Grant/Honorarium: Sanofi

]]> Tue, 1 Feb 2022 05:00:00 +0000 corporate.office@cua.org (Anil Kapoor, Luke Lavallee) https://cua.simplecast.com/episodes/practice-changing-publications-pcp-update-in-kidney-cancer-wsEObuAo Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position: Kidney Cancer Canada

Luke Lavallee
Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas
Grant/Honorarium: Sanofi

]]> Practice Changing Publications (PCP): Update in Kidney Cancer Anil Kapoor, Luke Lavallee 01:02:32 Practice Changing Publications (PCP): Update in Kidney Cancer Practice Changing Publications (PCP): Update in Kidney Cancer pcp, kidney cancer false full 30 d33db64b-15f0-4f39-94ed-2a0278f92203 The Year Ahead 2022: Global Economic Outlook Disclosures:

Derek Henderson
Banking relationship with TD

Christopher French
Advisory Boards: Astellas, AstraZeneca

]]> Mon, 24 Jan 2022 05:00:00 +0000 corporate.office@cua.org (Derek Henderson, Christopher French) https://cua.simplecast.com/episodes/the-year-ahead-2022-global-economic-outlook-IQqyw9Pb Disclosures:

Derek Henderson
Banking relationship with TD

Christopher French
Advisory Boards: Astellas, AstraZeneca

]]> The Year Ahead 2022: Global Economic Outlook Derek Henderson, Christopher French 00:57:15 The Year Ahead 2022: Global Economic Outlook The Year Ahead 2022: Global Economic Outlook global economic outlook false full 29 b3e612ba-0c9f-4d5c-b31e-41272cc568a7 Practice Changing Publications (PCP): Female Urology Disclosures:

Martine Jolivet
Advisory Board and/or Speaker Bureau: Allergan/Abbvie

Genevieve Nadeau
Clinical Trials: Contiform International
Advisory Board and/or Speaker Bureau: Pfizer, Boston Scientific, Astellas, Allergan/Abbvie, Searchlight Pharma

]]> Tue, 7 Dec 2021 05:00:00 +0000 corporate.office@cua.org (Martine Jolivet, Genevieve Nadeau) https://cua.simplecast.com/episodes/practice-changing-publications-pcp-female-urology-hk22ejas Disclosures:

Martine Jolivet
Advisory Board and/or Speaker Bureau: Allergan/Abbvie

Genevieve Nadeau
Clinical Trials: Contiform International
Advisory Board and/or Speaker Bureau: Pfizer, Boston Scientific, Astellas, Allergan/Abbvie, Searchlight Pharma

]]> Practice Changing Publications (PCP): Female Urology Martine Jolivet, Genevieve Nadeau 00:51:58 Practice Changing Publications (PCP): Female Urology Practice Changing Publications (PCP): Female Urology female urology, pcp false full 28 37adb68e-5029-45e6-908f-585a89eab8ce Management of Medication-Refractory Overactive Bladder (OAB) Disclosures:

Kevin Carlson
Advisory Board/Payment: Abbvie

Richard Baverstock
Advisory Board: Abbvie
Speakers Bureau: Astellas, Boston Scientific, Abbvie
Payment: Abbvie, Astellas, Bsci

Greg Baily
Advisory Board/ Speaker Bureau: Abbvie

]]> Wed, 24 Nov 2021 05:00:00 +0000 corporate.office@cua.org (Kevin Carlson, Greg Baily, Richard Baverstock) https://cua.simplecast.com/episodes/management-of-medication-refractory-overactive-bladder-oab-l56WXhgh Disclosures:

Kevin Carlson
Advisory Board/Payment: Abbvie

Richard Baverstock
Advisory Board: Abbvie
Speakers Bureau: Astellas, Boston Scientific, Abbvie
Payment: Abbvie, Astellas, Bsci

Greg Baily
Advisory Board/ Speaker Bureau: Abbvie

]]> Management of Medication-Refractory Overactive Bladder (OAB) Kevin Carlson, Greg Baily, Richard Baverstock 01:10:11 Management of Medication-Refractory Overactive Bladder (OAB) Management of Medication-Refractory Overactive Bladder (OAB) management of medication, refractory overactive bladder, oab false full 26 6d4bcf7e-a3b1-48b4-b755-895b1673c57f Management of Medication-Refractory Overactive Bladder (OAB) - French Disclosures:

Kevin Carlson
Advisroy Board/Payment: Abbvie

Richard Baverstock
Advisory Board: Abbvie
Speakers Bureau: Astellas, Boston Scientific, Abbvie
Payment: Abbvie, Astellas, Bsci

Greg Baily
Advisory Board/ Speaker Bureau: Abbvie

]]> Wed, 24 Nov 2021 05:00:00 +0000 corporate.office@cua.org (Kevin Carlson, Richard Baverstock, Greg Baily) https://cua.simplecast.com/episodes/management-of-medication-refractory-overactive-bladder-oab-french-3e4N46pn Disclosures:

Kevin Carlson
Advisroy Board/Payment: Abbvie

Richard Baverstock
Advisory Board: Abbvie
Speakers Bureau: Astellas, Boston Scientific, Abbvie
Payment: Abbvie, Astellas, Bsci

Greg Baily
Advisory Board/ Speaker Bureau: Abbvie

]]> Management of Medication-Refractory Overactive Bladder (OAB) - French Kevin Carlson, Richard Baverstock, Greg Baily 01:10:05 Management of Medication-Refractory Overactive Bladder (OAB) - French Management of Medication-Refractory Overactive Bladder (OAB) - French medication-refractory overactive bladder, management, oab false full 27 637321b3-55df-4b9d-ad36-077e2dfd08bc Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (English) Disclosures:

Neil Fleshner
Payment: Astellas, Janssen, Abbvie, Sanofi, Merck
Grant/Honorarium: Astellas, Janssen, Bayer
Investments: Verity Pharma
Clinical Trials: Astellas, Janssen, Bayer
Leadership Position: Point Biopharma

Urban Emmenegger
Advisory Boards: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Payment: Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Grant/Honorarium: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Clinical Trials: AstraZeneca, Bayer, Clovis, Janssen, Merck, Roche

Emily Thain
Advisory Boards: AstraZeneca/Merck, Pfizer
Honorarium: AstraZeneca/Merck, Pfizer

]]> Thu, 18 Nov 2021 05:00:00 +0000 corporate.office@cua.org (Neil Fleshner, Urban Emmenegger, Emily Thain) https://cua.simplecast.com/episodes/precision-medicine-in-prostate-cancer-multidisciplinary-perspectives-in-identifying-managing-and-optimizing-patient-care-english-PsmzfAXe Disclosures:

Neil Fleshner
Payment: Astellas, Janssen, Abbvie, Sanofi, Merck
Grant/Honorarium: Astellas, Janssen, Bayer
Investments: Verity Pharma
Clinical Trials: Astellas, Janssen, Bayer
Leadership Position: Point Biopharma

Urban Emmenegger
Advisory Boards: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Payment: Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Grant/Honorarium: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Clinical Trials: AstraZeneca, Bayer, Clovis, Janssen, Merck, Roche

Emily Thain
Advisory Boards: AstraZeneca/Merck, Pfizer
Honorarium: AstraZeneca/Merck, Pfizer

]]> Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (English) Neil Fleshner, Urban Emmenegger, Emily Thain 01:08:51 Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (English) Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (English) prostate cancer, multidisciplinary, patient care, precision medicine false full 25 0b0149b7-af22-4cbf-9b93-e97af1a8d9c3 Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (French) Conflits d'interests:

Fred Saad
Subventions/honoraires: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi

Zineb Hamilou
Remuneration: AstraZeneca, Sengen, EMD Serono
Essai Clinique: Sengen

Evan Weber
Subventions ou des honoraires: AstraZeneca/Merck

]]> Wed, 17 Nov 2021 05:00:00 +0000 corporate.office@cua.org (Fred Saad, Zineb Hamilou, Evan Weber) https://cua.simplecast.com/episodes/precision-medicine-in-prostate-cancer-multidisciplinary-perspectives-in-identifying-managing-and-optimizing-patient-care-french-p0m6wNY9 Conflits d'interests:

Fred Saad
Subventions/honoraires: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi

Zineb Hamilou
Remuneration: AstraZeneca, Sengen, EMD Serono
Essai Clinique: Sengen

Evan Weber
Subventions ou des honoraires: AstraZeneca/Merck

]]> Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (French) Fred Saad, Zineb Hamilou, Evan Weber 01:20:42 Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (French) Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (French) prostate cancer, multidisciplinary, patient care, precision medicine false full 24 b9746783-4960-477f-b6ab-6e83e1b6674b V2P2 2022 - Female Sexual Dysfunction Disclosures:

Ashley Cox
Advisory Board: Abbvie, Allergan

Rachel S. Rubin
Speakers Bureau: Sprout
Clinical Trials: Ipsen, Abbvie
Leadership/Board Position: ISSWSH

]]> Mon, 15 Nov 2021 05:00:00 +0000 corporate.office@cua.org (Ashley Cox, Rachel S. Rubin) https://cua.simplecast.com/episodes/v2p2-2022-female-sexual-dysfunction-Rh6DqhwO Disclosures:

Ashley Cox
Advisory Board: Abbvie, Allergan

Rachel S. Rubin
Speakers Bureau: Sprout
Clinical Trials: Ipsen, Abbvie
Leadership/Board Position: ISSWSH

]]> V2P2 2022 - Female Sexual Dysfunction Ashley Cox, Rachel S. Rubin 00:59:34 V2P2 2022 - Female Sexual Dysfunction V2P2 2022 - Female Sexual Dysfunction female sexual dysfunction, v2p2 2022 false full 22 41b61a7d-ee25-4975-b784-34f5579105e9 V2P2 2022 - Female Sexual Dysfunction [FR] Disclosures:

Ashley Cox
Advisory Board: Abbvie, Allergan

Rachel S. Rubin
Speakers Bureau: Sprout
Clinical Trials: Ipsen, Abbvie
Leadership/Board Position: ISSWSH

]]> Mon, 15 Nov 2021 05:00:00 +0000 corporate.office@cua.org (Ashley Cox, Rachel S. Rubin) https://cua.simplecast.com/episodes/v2p2-2022-female-sexual-dysfunction-chbe2psa-A6RSGVxG Disclosures:

Ashley Cox
Advisory Board: Abbvie, Allergan

Rachel S. Rubin
Speakers Bureau: Sprout
Clinical Trials: Ipsen, Abbvie
Leadership/Board Position: ISSWSH

]]> V2P2 2022 - Female Sexual Dysfunction [FR] Ashley Cox, Rachel S. Rubin 00:59:33 V2P2 2022 - Female Sexual Dysfunction V2P2 2022 - Female Sexual Dysfunction female sexual dysfunction, v2p2 2022 false full 23 582d6b7a-3573-4340-9ccb-beaba325133c CUA Practice Changing Publications (PCP): TESTIS CANCER Disclosures:

Armin Aprikian
Advisory boards: Abbvie, Astellas, Bayer
Grant/Honorarium: Abbvie, Astellas, Bayer, Sanofi, TerSera

Robert Hamilton
Advisory boards: Janssen, Astellas, Bayer, TerSera
Clinical Trials: Janssen, Bayer, Astellas

]]> Tue, 2 Nov 2021 04:00:00 +0000 corporate.office@cua.org (Armin Aprikian, Robert Hamilton) https://cua.simplecast.com/episodes/cua-practice-changing-publications-pcp-testis-cancer-nQ0c9GLW Disclosures:

Armin Aprikian
Advisory boards: Abbvie, Astellas, Bayer
Grant/Honorarium: Abbvie, Astellas, Bayer, Sanofi, TerSera

Robert Hamilton
Advisory boards: Janssen, Astellas, Bayer, TerSera
Clinical Trials: Janssen, Bayer, Astellas

]]> CUA Practice Changing Publications (PCP): TESTIS CANCER Armin Aprikian, Robert Hamilton 01:00:42 CUA Practice Changing Publications (PCP): TESTIS CANCER CUA Practice Changing Publications (PCP): TESTIS CANCER pcp, testis cancer false full 21 e6d6b01d-8ce4-4a6a-9bfb-c99c64daa5e9 CUA Practice Changing Publications (PCP): INFERTILITY Disclosures:

Armand Zini
Shareholder in YAD Tech - a neutraceuticals company

Jesse Ory
No disclosures

]]> Tue, 19 Oct 2021 04:00:00 +0000 corporate.office@cua.org (Armand Zini, Jesse Ory) https://cua.simplecast.com/episodes/cua-practice-changing-publications-pcp-infertility-8xMyU695 Disclosures:

Armand Zini
Shareholder in YAD Tech - a neutraceuticals company

Jesse Ory
No disclosures

]]> CUA Practice Changing Publications (PCP): INFERTILITY Armand Zini, Jesse Ory 01:03:12 CUA Practice Changing Publications (PCP): INFERTILITY CUA Practice Changing Publications (PCP): INFERTILITY infertility, pcp false full 20 5e9571e8-7cee-4bc9-a77b-66c0ccae87a7 CUA Highlights of ESMO 2021 - Prostate Cancer Session Disclosures:  

Sebastien J. Hotte
Research Funding (Institution): Astellas, AstraZeneca, Ayala, Bayer, BMS, Eisai, Exelixis, Janssen, Ipsen, Merck, Roche, Sanofi, SeaGen, SignalChem
Grants (Institution): BMS, Janssen, Bayer
Consultant/Honoraria (Self): Astellas, AtraZeneca ,Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche, SeaGen

Tamim Nizai
Honoraria/Research fun: Abbvie, Sanofi, TerSera, Knight Therapeutics, AstraZeneca, Bayer, Astellas, Janssen, Merck, Amgen, AAA

Andrea Kokorovic
No disclosures 

]]> Wed, 22 Sep 2021 04:00:00 +0000 corporate.office@cua.org (Sebastien J. Hotte, Tamim Nizai, Andrea Kokorovic) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2021-prostate-cancer-session-CNWX_MLT Disclosures:  

Sebastien J. Hotte
Research Funding (Institution): Astellas, AstraZeneca, Ayala, Bayer, BMS, Eisai, Exelixis, Janssen, Ipsen, Merck, Roche, Sanofi, SeaGen, SignalChem
Grants (Institution): BMS, Janssen, Bayer
Consultant/Honoraria (Self): Astellas, AtraZeneca ,Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche, SeaGen

Tamim Nizai
Honoraria/Research fun: Abbvie, Sanofi, TerSera, Knight Therapeutics, AstraZeneca, Bayer, Astellas, Janssen, Merck, Amgen, AAA

Andrea Kokorovic
No disclosures 

]]> CUA Highlights of ESMO 2021 - Prostate Cancer Session Sebastien J. Hotte, Tamim Nizai, Andrea Kokorovic 00:48:18 CUA Highlights of ESMO 2021 - Prostate Cancer Session CUA Highlights of ESMO 2021 - Prostate Cancer Session prostate cancer, esmo 2021 false full 16 854a4dd6-fb00-49f7-933d-986523718547 CUA Highlights of ESMO 2021 - Bladder Cancer Session Disclosures:

Girish Kilkarni
Advisory Boards: Janssen, Merck, Roche, Ferring, Astellas, Theralase
Grants/Honoraria: Abbvie, Sanofi, Ferring, TerSera, Knight Therapeutics, Verity
Clinical Trials: Merck, Astra Zeneca, Bristol Myers Squibb, Theralase, Janssen, Pfizer

Krista Noonan
Consulting/Honoraria: AstraZeneca, BMS, Janssen, Merck, Pfizer, EMD Serono
Research Support: Roche

]]> Wed, 22 Sep 2021 04:00:00 +0000 corporate.office@cua.org (Girish Kilkarni, Krista Noonan) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2021-bladder-cancer-session-_Pj5idaz Disclosures:

Girish Kilkarni
Advisory Boards: Janssen, Merck, Roche, Ferring, Astellas, Theralase
Grants/Honoraria: Abbvie, Sanofi, Ferring, TerSera, Knight Therapeutics, Verity
Clinical Trials: Merck, Astra Zeneca, Bristol Myers Squibb, Theralase, Janssen, Pfizer

Krista Noonan
Consulting/Honoraria: AstraZeneca, BMS, Janssen, Merck, Pfizer, EMD Serono
Research Support: Roche

]]> CUA Highlights of ESMO 2021 - Bladder Cancer Session Girish Kilkarni, Krista Noonan 00:29:09 CUA Highlights of ESMO 2021 - Bladder Cancer Session CUA Highlights of ESMO 2021 - Bladder Cancer Session bladder cancer, esmo 2021 false full 15 af3b1a69-9081-4120-b34f-244b2dd99e5e CUA Highlights of ESMO 2021 - Kidney Cancer Session Disclosures:  

Michael Leveridge
Ipsen - speaker session moderator 2019

Maryam Soleimani
Honorarium: Pfizer
Grant funding: Abbvie, Astellas, Bayer

Himu Lukka
No disclosures

]]> Wed, 22 Sep 2021 04:00:00 +0000 corporate.office@cua.org (Maryam Soleimani, Michael Leveridge, Himu Lukka) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2021-kidney-cancer-session-mnaMqYta Disclosures:  

Michael Leveridge
Ipsen - speaker session moderator 2019

Maryam Soleimani
Honorarium: Pfizer
Grant funding: Abbvie, Astellas, Bayer

Himu Lukka
No disclosures

]]> CUA Highlights of ESMO 2021 - Kidney Cancer Session Maryam Soleimani, Michael Leveridge, Himu Lukka 00:44:32 CUA Highlights of ESMO 2021 - Kidney Cancer Session CUA Highlights of ESMO 2021 - Kidney Cancer Session esmo 2021, kidney cancer false full 14 4b0d6fa1-7ee7-4276-81ca-639a0b39b603 CUA Highlights of ESMO 2021 - Kidney Cancer Session - French Disclosures:  

Michael Leveridge
Ipsen - speaker session moderator 2019

Maryam Soleimani
Honorarium: Pfizer
Grant funding: Abbvie, Astellas, Bayer

Himu Lukka
No disclosures

]]> Wed, 22 Sep 2021 04:00:00 +0000 corporate.office@cua.org (Michael Leveridge, Maryam Soleimani, Himu Lukka) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2021-kidney-cancer-session-french-p24n_5MS Disclosures:  

Michael Leveridge
Ipsen - speaker session moderator 2019

Maryam Soleimani
Honorarium: Pfizer
Grant funding: Abbvie, Astellas, Bayer

Himu Lukka
No disclosures

]]> CUA Highlights of ESMO 2021 - Kidney Cancer Session - French Michael Leveridge, Maryam Soleimani, Himu Lukka 00:44:37 CUA Highlights of ESMO 2021 - Kidney Cancer Session - French CUA Highlights of ESMO 2021 - Kidney Cancer Session - French esmo 2021, kidney cancer false full 17 01cdab61-6593-489d-beb0-6653d477032d CUA Highlights of ESMO 2021 - Bladder Cancer Session - French Disclosures:

Girish Kilkarni
Advisory Boards: Janssen, Merck, Roche, Ferring, Astellas, Theralase
Grants/Honoraria: Abbvie, Sanofi, Ferring, TerSera, Knight Therapeutics, Verity
Clinical Trials: Merck, Astra Zeneca, Bristol Myers Squibb, Theralase, Janssen, Pfizer

Krista Noonan
Consulting/Honoraria: AstraZeneca, BMS, Janssen, Merck, Pfizer, EMD Serono
Research Support: Roche

]]> Wed, 22 Sep 2021 04:00:00 +0000 corporate.office@cua.org (Girish Kilkarni, Krista Noonan) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2021-bladder-cancer-session-french-sbr_fLDP Disclosures:

Girish Kilkarni
Advisory Boards: Janssen, Merck, Roche, Ferring, Astellas, Theralase
Grants/Honoraria: Abbvie, Sanofi, Ferring, TerSera, Knight Therapeutics, Verity
Clinical Trials: Merck, Astra Zeneca, Bristol Myers Squibb, Theralase, Janssen, Pfizer

Krista Noonan
Consulting/Honoraria: AstraZeneca, BMS, Janssen, Merck, Pfizer, EMD Serono
Research Support: Roche

]]> CUA Highlights of ESMO 2021 - Bladder Cancer Session - French Girish Kilkarni, Krista Noonan 00:29:01 CUA Highlights of ESMO 2021 - Bladder Cancer Session - French CUA Highlights of ESMO 2021 - Bladder Cancer Session - French bladder cancer, esmo 2021 false full 18 131b4224-966c-43dd-b190-29ed219b429c CUA Highlights of ESMO 2021 - Prostate Cancer Session - French Disclosures:  

Sebastien J. Hotte
Research Funding (Institution): Astellas, AstraZeneca, Ayala, Bayer, BMS, Eisai, Exelixis, Janssen, Ipsen, Merck, Roche, Sanofi, SeaGen, SignalChem
Grants (Institution): BMS, Janssen, Bayer
Consultant/Honoraria (Self): Astellas, AtraZeneca ,Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche, SeaGen

Tamim Nizai
Honoraria/Research fun: Abbvie, Sanofi, TerSera, Knight Therapeutics, AstraZeneca, Bayer, Astellas, Janssen, Merck, Amgen, AAA

Andrea Kokorovic
No disclosures 

]]> Wed, 22 Sep 2021 04:00:00 +0000 corporate.office@cua.org (Sebastien J. Hotte, Tamim Nizai, Andrea Kokorovic) https://cua.simplecast.com/episodes/cua-highlights-of-esmo-2021-prostate-cancer-session-french-ySPRnfNB Disclosures:  

Sebastien J. Hotte
Research Funding (Institution): Astellas, AstraZeneca, Ayala, Bayer, BMS, Eisai, Exelixis, Janssen, Ipsen, Merck, Roche, Sanofi, SeaGen, SignalChem
Grants (Institution): BMS, Janssen, Bayer
Consultant/Honoraria (Self): Astellas, AtraZeneca ,Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche, SeaGen

Tamim Nizai
Honoraria/Research fun: Abbvie, Sanofi, TerSera, Knight Therapeutics, AstraZeneca, Bayer, Astellas, Janssen, Merck, Amgen, AAA

Andrea Kokorovic
No disclosures 

]]> CUA Highlights of ESMO 2021 - Prostate Cancer Session - French Sebastien J. Hotte, Tamim Nizai, Andrea Kokorovic 00:48:18 CUA Highlights of ESMO 2021 - Prostate Cancer Session - French CUA Highlights of ESMO 2021 - Prostate Cancer Session - French prostate cancer, esmo 2021 false full 19 a8cbb4f3-6f3d-4ba5-9281-befa81a33b65 CUA Q & A Series | Topic: Delay of Injection Delay of Injection (Q&A series)

0:00 - Ricardo Rendon

9:30 - Fred Saad

18:10 - Jasper Yuen

]]> Tue, 13 Jul 2021 04:00:00 +0000 corporate.office@cua.org (Jasper Yuen, Ricardo Rendon, Fred Saad) https://cua.simplecast.com/episodes/delay-of-injection-qa-series-T_xyxjsh Delay of Injection (Q&A series)

0:00 - Ricardo Rendon

9:30 - Fred Saad

18:10 - Jasper Yuen

]]> CUA Q & A Series | Topic: Delay of Injection Jasper Yuen, Ricardo Rendon, Fred Saad 00:26:23 Delay of Injection (Q&A series) Delay of Injection (Q&A series) urology, injection false bonus 220e20e4-b21f-4eac-9a9e-57ef58a5d995 Milestones in Advanced Bladder Cancer Podcast Host Disclosures:

Dr. Alimohamed has had a consulting or advisory role with Astellas Pharma, AstraZeneca, Janssen, Merck, Pfizer, and Sanofi Canada.

Dr. Lalani has received honoraria from Astellas Pharma, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche/Genentech, and TerSera; has had a consulting or advisory role with Abbvie, Astellas Pharma, Bayer, Bristol-Myers Squibb, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche/Genentech, and TerSera; and has received research funding from Bristol-Myers Squibb (Inst), Ipsen, Novartis, and Roche.

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

References:

Bellmunt J, et al. Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. J Clin Oncol. 2021;39(suppl 15): abstr 4532. https://bit.ly/3axehzb

Loriot Y, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348. https://www.nejm.org/doi/full/10.1056/NEJMoa1817323

O’Donnell PH, et al. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. J Clin Oncol. 2021;39(suppl 15): abstr 4508. https://bit.ly/3gyklv5

Powles T, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. https://www.nejm.org/doi/full/10.1056/NEJMoa2002788

Powles T, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125-1135. https://www.nejm.org/doi/full/10.1056/NEJMoa2035807

]]> Mon, 12 Jul 2021 15:26:33 +0000 corporate.office@cua.org (Aly-Khan Lalani, Nimira Alimohamed) https://cua.simplecast.com/episodes/milestones-in-advanced-bladder-cancer-NVUuWIgM Podcast Host Disclosures:

Dr. Alimohamed has had a consulting or advisory role with Astellas Pharma, AstraZeneca, Janssen, Merck, Pfizer, and Sanofi Canada.

Dr. Lalani has received honoraria from Astellas Pharma, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche/Genentech, and TerSera; has had a consulting or advisory role with Abbvie, Astellas Pharma, Bayer, Bristol-Myers Squibb, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche/Genentech, and TerSera; and has received research funding from Bristol-Myers Squibb (Inst), Ipsen, Novartis, and Roche.

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

References:

Bellmunt J, et al. Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. J Clin Oncol. 2021;39(suppl 15): abstr 4532. https://bit.ly/3axehzb

Loriot Y, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348. https://www.nejm.org/doi/full/10.1056/NEJMoa1817323

O’Donnell PH, et al. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. J Clin Oncol. 2021;39(suppl 15): abstr 4508. https://bit.ly/3gyklv5

Powles T, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. https://www.nejm.org/doi/full/10.1056/NEJMoa2002788

Powles T, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125-1135. https://www.nejm.org/doi/full/10.1056/NEJMoa2035807

]]> Milestones in Advanced Bladder Cancer Aly-Khan Lalani, Nimira Alimohamed 00:27:07 In this podcast, Dr. Nimira Alimohamed and Dr. Aly-Khan Lalani review the recent data from trials in advanced bladder cancer including the 5-year survival update of the KEYNOTE-045 trial presented at ASCO in June 2021. The hosts will discuss the impact of immunotherapy and other novel therapeutic strategies on the management of patients with advanced bladder cancer in Canada. In this podcast, Dr. Nimira Alimohamed and Dr. Aly-Khan Lalani review the recent data from trials in advanced bladder cancer including the 5-year survival update of the KEYNOTE-045 trial presented at ASCO in June 2021. The hosts will discuss the impact of immunotherapy and other novel therapeutic strategies on the management of patients with advanced bladder cancer in Canada. keynote trial, advanced bladder cancer false full 13 7f6371d8-3fa2-4f67-8e91-69aaffeabc3d CUA Highlights of ASCO 2021 - Prostate Cancer Session - French Disclosures:

Brita Danielson
Honoraria and speakers fees: Astellas, Amgen, Bayer, Ferring, Janssen

Nazanin Fallah-Rad
Consultancy/Advisory: Merck, Ipsen, Pfizer, Nekktar therapeutics
Honorariums: Bayer, Janssen, Ipsen, Astellas, Pfizer, Merck
Travel Grants: Nekktar Therapeutics

Vincent Fradet
Consultant, speaker or research agreement: Abbvie, Amgen, Astra Zeneca, Astellas, Bayer, Ferring, Janssen, Sanofi 

]]> Wed, 9 Jun 2021 04:00:00 +0000 corporate.office@cua.org (Brita Danielson, Vincent Fradet, Nazanin Fallah-Rad) https://cua.simplecast.com/episodes/cua-highlights-of-asco-2021-prostate-cancer-session-french-xiroUvPu Disclosures:

Brita Danielson
Honoraria and speakers fees: Astellas, Amgen, Bayer, Ferring, Janssen

Nazanin Fallah-Rad
Consultancy/Advisory: Merck, Ipsen, Pfizer, Nekktar therapeutics
Honorariums: Bayer, Janssen, Ipsen, Astellas, Pfizer, Merck
Travel Grants: Nekktar Therapeutics

Vincent Fradet
Consultant, speaker or research agreement: Abbvie, Amgen, Astra Zeneca, Astellas, Bayer, Ferring, Janssen, Sanofi 

]]> CUA Highlights of ASCO 2021 - Prostate Cancer Session - French Brita Danielson, Vincent Fradet, Nazanin Fallah-Rad 00:59:18 CUA Highlights of ASCO 2021 - Prostate Cancer Session - French CUA Highlights of ASCO 2021 - Prostate Cancer Session - French prostate cancer, asco 2021 false full 10 d8f317b3-70af-4d74-873e-33ac23ea6ba5 CUA Highlights of ASCO 2021 - Kidney Cancer Session - French Disclosures:

Daniel Heng
Consultancies and advisory boards: BMS, Merck, Pfizer, Novartis, Eisai, Exilexas, Ipsen

Anand Swaminath
Advisory board: Astrazeneca
Expert Speaker: Astrazeneca, BMS, Eisai
Grants (in kind): BMS, Roche

Rodney Breau
No disclosures

]]> Wed, 9 Jun 2021 04:00:00 +0000 corporate.office@cua.org (Daniel Heng, Anand Swaminath, Rodney Breau) https://cua.simplecast.com/episodes/cua-highlights-of-asco-2021-kidney-cancer-session-french-1XaX5zju Disclosures:

Daniel Heng
Consultancies and advisory boards: BMS, Merck, Pfizer, Novartis, Eisai, Exilexas, Ipsen

Anand Swaminath
Advisory board: Astrazeneca
Expert Speaker: Astrazeneca, BMS, Eisai
Grants (in kind): BMS, Roche

Rodney Breau
No disclosures

]]> CUA Highlights of ASCO 2021 - Kidney Cancer Session - French Daniel Heng, Anand Swaminath, Rodney Breau 00:52:35 CUA Highlights of ASCO 2021 - Kidney Cancer Session - French CUA Highlights of ASCO 2021 - Kidney Cancer Session - French asco 2021, kidney cance false full 11 c5ba364f-bafd-491a-9e2e-4f6a63fb6bcb CUA Highlights of ASCO 2021 - Kidney Cancer Session Disclosures:

Daniel Heng
Consultancies and advisory boards: BMS, Merck, Pfizer, Novartis, Eisai, Exilexas, Ipsen

Anand Swaminath
Advisory board: Astrazeneca
Expert Speaker: Astrazeneca, BMS, Eisai
Grants (in kind): BMS, Roche

Rodney Breau
No disclosures

]]> Wed, 9 Jun 2021 04:00:00 +0000 corporate.office@cua.org (Daniel Heng, Anand Swaminath, Rodney Breau) https://cua.simplecast.com/episodes/cua-highlights-of-asco-2021-kidney-cancer-session-dD2Z2UUM Disclosures:

Daniel Heng
Consultancies and advisory boards: BMS, Merck, Pfizer, Novartis, Eisai, Exilexas, Ipsen

Anand Swaminath
Advisory board: Astrazeneca
Expert Speaker: Astrazeneca, BMS, Eisai
Grants (in kind): BMS, Roche

Rodney Breau
No disclosures

]]> CUA Highlights of ASCO 2021 - Kidney Cancer Session Daniel Heng, Anand Swaminath, Rodney Breau 00:52:26 CUA Highlights of ASCO 2021 - Kidney Cancer Session CUA Highlights of ASCO 2021 - Kidney Cancer Session asco 2021, kidney cancer false full 8 40fa4f80-c2db-480e-a4d7-ddd75e99e32f CUA Highlights of ASCO 2021 - Bladder Cancer session Disclosures:

Fabio Cury
Educational grants: Sanofi S.A., Boston Scientific
Honoraria/Travel Support: Varian Medical Systems, Bayer AG, Abbvie

Neil Fleshner
Payment: Astellas, Janssen, Abbvie, Sanofi, Merck
Grant/Honorarium: Astellas, Janssen, Bayey
Investments: Verity Pharma
Clinical Trials: Astellas, Janssen, Bayer
Leadership position: Point Biopharma

Di (Maria) Jiang
Speaker's honoraria: Ipsen, Janssen, Bayer

]]> Wed, 9 Jun 2021 04:00:00 +0000 corporate.office@cua.org (Fabio Cury, Neil Fleshner, Di (Maria) Jiang) https://cua.simplecast.com/episodes/cua-highlights-of-asco-2021-bladder-cancer-session-rR_7By8G Disclosures:

Fabio Cury
Educational grants: Sanofi S.A., Boston Scientific
Honoraria/Travel Support: Varian Medical Systems, Bayer AG, Abbvie

Neil Fleshner
Payment: Astellas, Janssen, Abbvie, Sanofi, Merck
Grant/Honorarium: Astellas, Janssen, Bayey
Investments: Verity Pharma
Clinical Trials: Astellas, Janssen, Bayer
Leadership position: Point Biopharma

Di (Maria) Jiang
Speaker's honoraria: Ipsen, Janssen, Bayer

]]> CUA Highlights of ASCO 2021 - Bladder Cancer session Fabio Cury, Neil Fleshner, Di (Maria) Jiang 00:59:45 CUA Highlights of ASCO 2021 - Bladder Cancer session CUA Highlights of ASCO 2021 - Bladder Cancer session asco 2021, bladder cancer false full 9 c0d5c6d5-8d5b-4d6a-8f98-6e532701b8db CUA Highlights of ASCO 2021 - Prostate Cancer Session Disclosures:

Brita Danielson
Honoraria and speakers fees: Astellas, Amgen, Bayer, Ferring, Janssen

Nazanin Fallah-Rad
Consultancy/Advisory: Merck, Ipsen, Pfizer, Nekktar therapeutics
Honorariums: Bayer, Janssen, Ipsen, Astellas, Pfizer, Merck
Travel Grants: Nekktar Therapeutics

Vincent Fradet
Consultant, speaker or research agreement: Abbvie, Amgen, Astra Zeneca, Astellas, Bayer, Ferring, Janssen, Sanofi 

]]> Wed, 9 Jun 2021 04:00:00 +0000 corporate.office@cua.org (Brita Danielson, Nazanin Fallah-Rad, Vincent Fradet) https://cua.simplecast.com/episodes/cua-highlights-of-asco-2021-prostate-cancer-session-mPmLISgr Disclosures:

Brita Danielson
Honoraria and speakers fees: Astellas, Amgen, Bayer, Ferring, Janssen

Nazanin Fallah-Rad
Consultancy/Advisory: Merck, Ipsen, Pfizer, Nekktar therapeutics
Honorariums: Bayer, Janssen, Ipsen, Astellas, Pfizer, Merck
Travel Grants: Nekktar Therapeutics

Vincent Fradet
Consultant, speaker or research agreement: Abbvie, Amgen, Astra Zeneca, Astellas, Bayer, Ferring, Janssen, Sanofi 

]]> CUA Highlights of ASCO 2021 - Prostate Cancer Session Brita Danielson, Nazanin Fallah-Rad, Vincent Fradet 00:59:07 CUA Highlights of ASCO 2021 - Prostate Cancer Session CUA Highlights of ASCO 2021 - Prostate Cancer Session prostate cancer, asco 2021 false full 7 870426e1-9036-40cc-bc7e-1dd349acf76e CUA Highlights of ASCO 2021 - Bladder Cancer session - French Disclosures:

Fabio Cury
Educational grants: Sanofi S.A., Boston Scientific
Honoraria/Travel Support: Varian Medical Systems, Bayer AG, Abbvie

Neil Fleshner
Payment: Astellas, Janssen, Abbvie, Sanofi, Merck
Grant/Honorarium: Astellas, Janssen, Bayey
Investments: Verity Pharma
Clinical Trials: Astellas, Janssen, Bayer
Leadership position: Point Biopharma

Di (Maria) Jiang
Speaker's honoraria: Ipsen, Janssen, Bayer

]]> Wed, 9 Jun 2021 04:00:00 +0000 corporate.office@cua.org (Fabio Cury, Neil Fleshner, Di (Maria) Jiang) https://cua.simplecast.com/episodes/cua-highlights-of-asco-2021-bladder-cancer-session-french-GvpBhZp_ Disclosures:

Fabio Cury
Educational grants: Sanofi S.A., Boston Scientific
Honoraria/Travel Support: Varian Medical Systems, Bayer AG, Abbvie

Neil Fleshner
Payment: Astellas, Janssen, Abbvie, Sanofi, Merck
Grant/Honorarium: Astellas, Janssen, Bayey
Investments: Verity Pharma
Clinical Trials: Astellas, Janssen, Bayer
Leadership position: Point Biopharma

Di (Maria) Jiang
Speaker's honoraria: Ipsen, Janssen, Bayer

]]> CUA Highlights of ASCO 2021 - Bladder Cancer session - French Fabio Cury, Neil Fleshner, Di (Maria) Jiang 00:59:45 CUA Highlights of ASCO 2021 - Bladder Cancer session - French CUA Highlights of ASCO 2021 - Bladder Cancer session - French asco 2021, bladder cancer false full 12 82030a49-5fa6-4031-8899-fdea244b6de9 CUA Practice Changing Publications (PCP) in Pediatric Urology Disclosures:
No disclosures

]]> Thu, 6 May 2021 04:00:00 +0000 corporate.office@cua.org (Peter Metcalfe, Mira Keyes) https://cua.simplecast.com/episodes/cua-practice-changing-publications-pcp-in-pediatric-urology-e_yw_MBZ Disclosures:
No disclosures

]]> CUA Practice Changing Publications (PCP) in Pediatric Urology Peter Metcalfe, Mira Keyes 01:01:49 CUA Practice Changing Publications (PCP) in Pediatric Urology CUA Practice Changing Publications (PCP) in Pediatric Urology pediatric urology, pcp false full 6 f54d026d-78dc-45e1-a26d-cf71b2ddd8fc CUA Practice Changing Publications (PCP): An Update in Men's Health Disclosures:

Jeffrey Campbell
Advisory Board/Grant/Honorarium: Boston Scientific, Abbvie, Paladin Labs

Premal Patel
Advisory Board/Grant/Honorarium: Boston Scientific

]]> Wed, 28 Apr 2021 04:00:00 +0000 corporate.office@cua.org (Jeffrey Campbell, Premal Patel) https://cua.simplecast.com/episodes/cua-practice-changing-publications-pcp-mens-health-Ch6T3hMM Disclosures:

Jeffrey Campbell
Advisory Board/Grant/Honorarium: Boston Scientific, Abbvie, Paladin Labs

Premal Patel
Advisory Board/Grant/Honorarium: Boston Scientific

]]> CUA Practice Changing Publications (PCP): An Update in Men's Health Jeffrey Campbell, Premal Patel 00:53:06 CUA Practice Changing Publications (PCP): An Update in Men's Health CUA Practice Changing Publications (PCP): An Update in Men's Health men's health, pcp false full 5 8039664f-c93d-456b-9b27-16b0613315d4 Practice Changing Publications (PCP): Management of MIBC Disclosures:

Girish Kilkarni
Advisory Boards: Janssen, Merck, Roche, Ferring, Astellas, Theralase
Grants/Honoraria: Abbvie, Sanofi, Ferring, TerSera
Clinical Trials: Merck, Astra Zeneca, Bristol Myers Squibb, Theralase

Ross Mason
Advisory Boards: Astellas, Abbvie, TerSara, Verity
Grants/Honoraria: Abbvie, Sanofi, TerSara, Bladder Cancer Canada
Clinical Trials: Merck, Bayer

]]> Thu, 1 Apr 2021 04:00:00 +0000 corporate.office@cua.org (Girish Kilkarni, Ross Mason) https://cua.simplecast.com/episodes/practice-changing-publications-pcp-management-of-mibc-aasuu0bQ Disclosures:

Girish Kilkarni
Advisory Boards: Janssen, Merck, Roche, Ferring, Astellas, Theralase
Grants/Honoraria: Abbvie, Sanofi, Ferring, TerSera
Clinical Trials: Merck, Astra Zeneca, Bristol Myers Squibb, Theralase

Ross Mason
Advisory Boards: Astellas, Abbvie, TerSara, Verity
Grants/Honoraria: Abbvie, Sanofi, TerSara, Bladder Cancer Canada
Clinical Trials: Merck, Bayer

]]> Practice Changing Publications (PCP): Management of MIBC Girish Kilkarni, Ross Mason 01:00:26 Practice Changing Publications (PCP): Management of MIBC Practice Changing Publications (PCP): Management of MIBC mibc, urology, pcp false full 4 4a319314-9611-470e-a8a1-05dc0cf0fe5f Practice Changing Publications (PCP): Urolithiasis Disclosures:
Andrea G. Lantz Powers
none

Ben Chew
Consultant: Bard Medical, Boston Scientific, Cook Medical, Olympus, Poly-Med, Adva-TEC inc., Auris Surgical, Coloplast
Speakers Bureau: Boston Scientific, Cook Medical, Olympus, Coloplast
Grants: Boston Scientific, Cook Medical, Olympus
Clinical Trials: Olympus, Bosotn Scientific, Cook Medical

]]> Mon, 1 Mar 2021 05:00:00 +0000 corporate.office@cua.org (Ben Chew, Andrea G. Lantz Powers) https://cua.simplecast.com/episodes/practice-changing-publications-pcp-urolithiasis-sdnVTPpb Disclosures:
Andrea G. Lantz Powers
none

Ben Chew
Consultant: Bard Medical, Boston Scientific, Cook Medical, Olympus, Poly-Med, Adva-TEC inc., Auris Surgical, Coloplast
Speakers Bureau: Boston Scientific, Cook Medical, Olympus, Coloplast
Grants: Boston Scientific, Cook Medical, Olympus
Clinical Trials: Olympus, Bosotn Scientific, Cook Medical

]]> Practice Changing Publications (PCP): Urolithiasis Ben Chew, Andrea G. Lantz Powers 01:01:16 Practice Changing Publications (PCP): Urolithiasis Practice Changing Publications (PCP): Urolithiasis urolithiasis, urology, pcp false full 3 ff9c54d4-659b-49df-8127-92b037437837 Simplifying mCSPC: Improving Patient Management and Outcomes Disclosures:

Ricardo Rendon
Advisory Board: Astellas, Amgen, Abbvie, Janssen, Bayer, AstraZeneca, Ferring, Sanofi
Speakers Bureau: Astellas, Amgen, Ferring, Janssen
Clinical Trials: Amgen, Astellas, Abbvie, Ferring, Janssen, AstraZeneca, Sanofi, Pfizer, Myovant 

]]> Wed, 24 Feb 2021 05:00:00 +0000 corporate.office@cua.org (Ricardo Rendon) https://cua.simplecast.com/episodes/simplifying-mcspc-improving-patient-management-and-outcomes-oFqfWYp8 Disclosures:

Ricardo Rendon
Advisory Board: Astellas, Amgen, Abbvie, Janssen, Bayer, AstraZeneca, Ferring, Sanofi
Speakers Bureau: Astellas, Amgen, Ferring, Janssen
Clinical Trials: Amgen, Astellas, Abbvie, Ferring, Janssen, AstraZeneca, Sanofi, Pfizer, Myovant 

]]> Simplifying mCSPC: Improving Patient Management and Outcomes Ricardo Rendon 00:40:10 Simplifying mCSPC: Improving Patient Management and Outcomes Simplifying mCSPC: Improving Patient Management and Outcomes patient management, mcspc false full 2 b248b2dd-f66f-4948-a210-a6e9165ca441 Practice Changing Publications (PCP) in Functional Urology: A Year in Review Disclosures:

Ashley Cox
Advisory Board: Astellas, Pfizer, Teva
Clinical Trial: Aquinox

Laura Nguyen
Speakers Bureau: Astella, Pfizer
Grant/Honorarium: Ontario College of Family Physicians

 

]]> Tue, 26 Jan 2021 05:00:00 +0000 corporate.office@cua.org (Ashley Cox, Laura Nguyen) https://cua.simplecast.com/episodes/practice-changing-publications-pcp-in-functional-urology-a-year-in-review-04guidM0 Disclosures:

Ashley Cox
Advisory Board: Astellas, Pfizer, Teva
Clinical Trial: Aquinox

Laura Nguyen
Speakers Bureau: Astella, Pfizer
Grant/Honorarium: Ontario College of Family Physicians

 

]]> Practice Changing Publications (PCP) in Functional Urology: A Year in Review Ashley Cox, Laura Nguyen 01:00:43 Practice Changing Publications (PCP) in Functional Urology: A Year in Review Practice Changing Publications (PCP) in Functional Urology: A Year in Review functional urology, urology, pcp false full 1 ac0d8c50-6016-448d-97aa-6b79e1cacb5d Launching the CUA Podcast! Fri, 1 Jan 2021 23:45:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/launching-the-cua-podcast-g69E8ySf Launching the CUA Podcast! Canadian Urological Association / L'Association des urologues du Canada 00:00:36 The Canadian Urological Association is excited to be launching its new podcast series! Subscribe today to make sure you stay up to date with the latest episodes from CUA – The voice of urology in Canada. Visit cua.org for more info! The Canadian Urological Association is excited to be launching its new podcast series! Subscribe today to make sure you stay up to date with the latest episodes from CUA – The voice of urology in Canada. Visit cua.org for more info! urology, urologists false full 0 e7ac155c-1629-4825-9154-432f9d63f781 CUA Q & A Series | Topic: Low T and Breakthrough Low T and Breakthrough (Q&A Series)

0:00 - Neil Fleshner

1:07 - Martin Gleave

4:07 - Mira Keyes

9:00 - Laurence Klotz

12:32 - Abdenour Nabid

16:50 - Tamim Niazi

20:55 - Fred Saad

23:20 - Bobby Shayegan

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Fred Saad, Laurence Klotz, Neil Fleshner, Martin Gleave, Abdenour Nabid, Tamim Niazi, Mira Keyes, Bobby Shayegan) https://cua.simplecast.com/episodes/low-t-and-breakthrough-qa-series-3Cpali5W Low T and Breakthrough (Q&A Series)

0:00 - Neil Fleshner

1:07 - Martin Gleave

4:07 - Mira Keyes

9:00 - Laurence Klotz

12:32 - Abdenour Nabid

16:50 - Tamim Niazi

20:55 - Fred Saad

23:20 - Bobby Shayegan

]]> CUA Q & A Series | Topic: Low T and Breakthrough Fred Saad, Laurence Klotz, Neil Fleshner, Martin Gleave, Abdenour Nabid, Tamim Niazi, Mira Keyes, Bobby Shayegan 00:30:48 Low T and Breakthrough (Q&A Series) Low T and Breakthrough (Q&A Series) urology, breakthrough, low t false bonus 5fdec96f-40f4-4a9b-90eb-95b27df699b7 Fred Saad | Intermittent vs Continuous Androgen Deprivation in Prostate Cancer | Q&A Series Intermittent vs Continuous Androgen Deprivation in Prostate Cancer - Fred Saad

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Fred Saad) https://cua.simplecast.com/episodes/intermittent-vs-continuous-androgen-deprivation-in-prostate-cancer-fred-saad-iH5R_0_b Intermittent vs Continuous Androgen Deprivation in Prostate Cancer - Fred Saad

]]> Fred Saad | Intermittent vs Continuous Androgen Deprivation in Prostate Cancer | Q&A Series Fred Saad 00:06:16 Fred Saad | Intermittent vs Continuous Androgen Deprivation in Prostate Cancer | Q&A Series Fred Saad | Intermittent vs Continuous Androgen Deprivation in Prostate Cancer | Q&A Series prostate cancer, androgen deprivation, intermittent, continuous false bonus ffd30291-e9d8-4f19-9cc7-ee376293e695 Mira Keyes | Intermittent vs Continuous Androgen Deprivation in Prostate Cancer | Q&A Series Intermittent vs Continuous Androgen Deprivation in Prostate Cancer - Mira Keyes

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Mira Keyes) https://cua.simplecast.com/episodes/intermittent-vs-continuous-androgen-deprivation-in-prostate-cancer-mira-keyes-D0cxfDbX Intermittent vs Continuous Androgen Deprivation in Prostate Cancer - Mira Keyes

]]> Mira Keyes | Intermittent vs Continuous Androgen Deprivation in Prostate Cancer | Q&A Series Mira Keyes 00:07:28 Mira Keyes | Intermittent vs Continuous Androgen Deprivation in Prostate Cancer | Q&A Series Mira Keyes | Intermittent vs Continuous Androgen Deprivation in Prostate Cancer | Q&A Series prostate cancer, androgen deprivation, intermittent, continuous false bonus 1e6348fd-ba1b-42a1-be76-4b422a804d54 Fred Saad | Early vs Delayed Therapy | Q&A Series Fred Saad | Early vs Delayed Therapy | Q&A Series

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Fred Saad) https://cua.simplecast.com/episodes/early-vs-delayed-therapy-fred-saad-q7fPyrUH Fred Saad | Early vs Delayed Therapy | Q&A Series

]]> Fred Saad | Early vs Delayed Therapy | Q&A Series Fred Saad 00:06:24 Early vs Delayed Therapy - Fred Saad Early vs Delayed Therapy - Fred Saad therapy, early, delayed false bonus 73c00c89-3b55-4268-bfc8-c2b82e8b54ea Laurence Klotz | Early vs Delayed Therapy | Q&A Series Early vs Delayed Therapy - Laurence Klotz

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Laurence Klotz) https://cua.simplecast.com/episodes/early-vs-delayed-therapy-laurence-klotz-k3bAwKJv Early vs Delayed Therapy - Laurence Klotz

]]> Laurence Klotz | Early vs Delayed Therapy | Q&A Series Laurence Klotz 00:08:00 Laurence Klotz | Early vs Delayed Therapy | Q&A Series Laurence Klotz | Early vs Delayed Therapy | Q&A Series therapy, early, delayed false bonus c90dddd2-4fc5-4df9-87a1-3e2ca46d56b0 Martin Gleave | Early vs Delayed Therapy | Q&A Series Early vs Delayed Therapy - Martin Gleave

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Martin Gleave) https://cua.simplecast.com/episodes/early-vs-delayed-therapy-martin-gleave-__zuTKYs Early vs Delayed Therapy - Martin Gleave

]]> Martin Gleave | Early vs Delayed Therapy | Q&A Series Martin Gleave 00:09:00 Martin Gleave | Early vs Delayed Therapy | Q&A Series Martin Gleave | Early vs Delayed Therapy | Q&A Series therapy, early, delayed false full 46 5ce05b55-e340-442a-b5a0-c1040649e2ef Bobby Shayegan | Low T & Breakthrough | CUA Q&A Series Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Bobby Shayegan) https://cua.simplecast.com/episodes/low-t-breakthrough-bobby-shayegan-RA4KqF2X Bobby Shayegan | Low T & Breakthrough | CUA Q&A Series Bobby Shayegan 00:07:44 Bobby Shayegan | Low T & Breakthrough | CUA Q&A Series Bobby Shayegan | Low T & Breakthrough | CUA Q&A Series breakthrough, low t false bonus 7f9d92df-de89-40c1-a686-4c9c13fcf849 Tamim Niazi | ADT Duration with Radiation | Q&A Series ADT Duration with Radiation - Tamim Niazi

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Tamim Niazi) https://cua.simplecast.com/episodes/adt-duration-with-radiation-tamim-niazi-ne8A9DQh ADT Duration with Radiation - Tamim Niazi

]]> Tamim Niazi | ADT Duration with Radiation | Q&A Series Tamim Niazi 00:08:04 Tamim Niazi | ADT Duration with Radiation | Q&A Series Tamim Niazi | ADT Duration with Radiation | Q&A Series adt, duration, radiation false bonus 24df3523-cb97-4a75-a19f-4be7b42e1f39 Abdenour Nabid | ADT Duration with Radiation | Q&A Series ADT Duration with Radiation - Abdenour Nabid

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Abdenour Nabid) https://cua.simplecast.com/episodes/adt-duration-with-radiation-abdenour-nabid-loj8OPB_ ADT Duration with Radiation - Abdenour Nabid

]]> Abdenour Nabid | ADT Duration with Radiation | Q&A Series Abdenour Nabid 00:05:16 Abdenour Nabid | ADT Duration with Radiation | Q&A Series Abdenour Nabid | ADT Duration with Radiation | Q&A Series adt, duration, radiation false bonus e0863efb-07a0-4d91-a529-ed8449853030 Neil Fleshner | Low T & Breakthrough | Q&A Series Low T & Breakthrough - Neil Fleshner

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Neil Fleshner) https://cua.simplecast.com/episodes/low-t-breakthrough-neil-fleshner-sST21woX Low T & Breakthrough - Neil Fleshner

]]> Neil Fleshner | Low T & Breakthrough | Q&A Series Neil Fleshner 00:01:26 Neil Fleshner | Low T & Breakthrough | Q&A Series Neil Fleshner | Low T & Breakthrough | Q&A Series breakthrough, low t false bonus db38d01c-d42b-4550-974b-fecb177f79af Laurence Klotz | Low T & Breakthrough | Q&A Series Low T & Breakthrough - Laurence Klotz

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Laurence Klotz) https://cua.simplecast.com/episodes/low-t-breakthrough-laurence-klotz-vFYcJYKz Low T & Breakthrough - Laurence Klotz

]]> Laurence Klotz | Low T & Breakthrough | Q&A Series Laurence Klotz 00:03:59 Laurence Klotz | Low T & Breakthrough | Q&A Series Laurence Klotz | Low T & Breakthrough | Q&A Series breakthrough, low t false bonus 6b9fc32b-a027-4c4e-abad-87a221b8bbf2 CUA Q & A Series | Topic: Early vs Delayed Therapy Early vs Delayed Therapy (Q&A Series)

0:00 - Neil Fleshner

3:27 - Martin Gleave

11:52 - Mira Keyes

21:10 - Laurence Klotz

28:40 - Abdenour Nabid

37:10 - Tamim Niazi

44:05 - Fred Saad

49:55 - Bobby Shayegan

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Neil Fleshner, Fred Saad, Tamim Niazi, Martin Gleave, Laurence Klotz, Mira Keyes, Abdenour Nabid, Bobby Shayegan) https://cua.simplecast.com/episodes/early-vs-delayed-therapy-qa-series-bFux4Or9 Early vs Delayed Therapy (Q&A Series)

0:00 - Neil Fleshner

3:27 - Martin Gleave

11:52 - Mira Keyes

21:10 - Laurence Klotz

28:40 - Abdenour Nabid

37:10 - Tamim Niazi

44:05 - Fred Saad

49:55 - Bobby Shayegan

]]> CUA Q & A Series | Topic: Early vs Delayed Therapy Neil Fleshner, Fred Saad, Tamim Niazi, Martin Gleave, Laurence Klotz, Mira Keyes, Abdenour Nabid, Bobby Shayegan 00:59:41 Early vs Delayed Therapy (Q&A Series) Early vs Delayed Therapy (Q&A Series) urology, early, delayed false bonus 06bccf07-1a47-46e3-ac8b-3548f2a91b09 CUA Q & A Series | Topic: Androgen Deprivation Therapy Androgen Deprivation Therapy (Q&A series)

0:00 - Mira Keyes

9:53 - Abdenour Nabid

14:55 - Tamim Niazi

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Abdenour Nabid, Mira Keyes, Tamim Niazi) https://cua.simplecast.com/episodes/androgen-deprivation-therapy-qa-series-lbwdkiWv Androgen Deprivation Therapy (Q&A series)

0:00 - Mira Keyes

9:53 - Abdenour Nabid

14:55 - Tamim Niazi

]]> CUA Q & A Series | Topic: Androgen Deprivation Therapy Abdenour Nabid, Mira Keyes, Tamim Niazi 00:22:28 Androgen Deprivation Therapy (Q&A series) Androgen Deprivation Therapy (Q&A series) androgen deprivation, urology false bonus ebc44ded-f168-400d-ad5d-9c467c0b98ab CUA Q & A Series | Topic: Intermittent vs Continuous Intermittent vs Continuous (Q&A Series)

0:00 - Neil Fleshner

2:50 - Martin Gleave

10:30 - Mira Keyes

17:30 - Laurence Klotz

24:30 - Abdenour Nabid

29:35 - Tamim Niazi

35:05 - Fred Saad

40:50 - Bobby Shayegan

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Mira Keyes, Bobby Shayegan, Martin Gleave, Tamim Niazi, Laurence Klotz, Abdenour Nabid, Neil Fleshner, Fred Saad) https://cua.simplecast.com/episodes/intermittent-vs-continuous-qa-series-JUfQsNZy Intermittent vs Continuous (Q&A Series)

0:00 - Neil Fleshner

2:50 - Martin Gleave

10:30 - Mira Keyes

17:30 - Laurence Klotz

24:30 - Abdenour Nabid

29:35 - Tamim Niazi

35:05 - Fred Saad

40:50 - Bobby Shayegan

]]> CUA Q & A Series | Topic: Intermittent vs Continuous Mira Keyes, Bobby Shayegan, Martin Gleave, Tamim Niazi, Laurence Klotz, Abdenour Nabid, Neil Fleshner, Fred Saad 00:56:56 Intermittent vs Continuous (Q&A Series) Intermittent vs Continuous (Q&A Series) intermittent, continuous, urology false bonus 104918c6-fb24-4cd1-8f73-8d230147cf49 CUA Q & A Series | Topic: Evolution of Landscape Evolution of Landscape (Q&A Series)

0:00 - Neil Fleshner

3:30 - Martin Gleave

11:20 - Mira Keyes

15:40 - Laurence Klotz

20:34 - Abdenour Nabid

26:25 - Tamim Niazi

33:35 - Fred Saad

38:35 - Bobby Shayegan

]]> Sat, 5 Dec 2020 05:00:00 +0000 corporate.office@cua.org (Laurence Klotz, Neil Fleshner, Mira Keyes, Tamim Niazi, Abdenour Nabid, Fred Saad, Martin Gleave, Bobby Shayegan) https://cua.simplecast.com/episodes/evolution-of-landscape-qa-series-m_Dv1WMj Evolution of Landscape (Q&A Series)

0:00 - Neil Fleshner

3:30 - Martin Gleave

11:20 - Mira Keyes

15:40 - Laurence Klotz

20:34 - Abdenour Nabid

26:25 - Tamim Niazi

33:35 - Fred Saad

38:35 - Bobby Shayegan

]]> CUA Q & A Series | Topic: Evolution of Landscape Laurence Klotz, Neil Fleshner, Mira Keyes, Tamim Niazi, Abdenour Nabid, Fred Saad, Martin Gleave, Bobby Shayegan 00:46:42 Evolution of Landscape (Q&A Series) Evolution of Landscape (Q&A Series) urology false bonus 07c6759b-fc49-47ac-821c-ac1b5c4ef707 Qu'est-ce qui rend l'urologie spéciale? (Qu'est-ce que l'urologie) Qu'est-ce qui rend l'urologie spéciale? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Fri, 4 Sep 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/quest-ce-qui-rend-lurologie-speciale-quest-ce-que-lurologie-0mqdLH9E Qu'est-ce qui rend l'urologie spéciale? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Qu'est-ce qui rend l'urologie spéciale? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:02:25 Qu'est-ce qui rend l'urologie spéciale? (Qu'est-ce que l'urologie) Qu'est-ce qui rend l'urologie spéciale? (Qu'est-ce que l'urologie) false bonus 3322354c-7783-420e-865c-48501cb9572a Trouvez-vous que l'urologie donne une carrière enrichissante? (Qu'est-ce que l'urologie) Trouvez-vous que l'urologie donne une carrière enrichissante? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/trouvez-vous-que-lurologie-donne-une-carriere-enrichissante-quest-ce-que-lurologie-bec0f9S7 Trouvez-vous que l'urologie donne une carrière enrichissante? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Trouvez-vous que l'urologie donne une carrière enrichissante? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:24 Trouvez-vous que l'urologie donne une carrière enrichissante? (Qu'est-ce que l'urologie) Trouvez-vous que l'urologie donne une carrière enrichissante? (Qu'est-ce que l'urologie) false bonus e792991f-e3a1-4583-b69f-c7ea7b2101b6 Quelles qualitiés font un grand urologue? (Qu'est-ce que l'urologie) Quelles qualitiés font un grand urologue? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/quelles-qualities-font-un-grand-urologue-quest-ce-que-lurologie-MGYVhhNg Quelles qualitiés font un grand urologue? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Quelles qualitiés font un grand urologue? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:42 Quelles qualitiés font un grand urologue? (Qu'est-ce que l'urologie) Quelles qualitiés font un grand urologue? (Qu'est-ce que l'urologie) false bonus 1994d2ce-7d2e-4c22-8814-c6b7c1bb9320 À quoi ressemble votre horarie hebdomadaire? (Qu'est-ce que l'urologie) À quoi ressemble votre horarie hebdomadaire? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/a-quoi-ressemble-votre-horarie-hebdomadaire-quest-ce-que-lurologie-_iKMAEaz À quoi ressemble votre horarie hebdomadaire? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> À quoi ressemble votre horarie hebdomadaire? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:50 À quoi ressemble votre horarie hebdomadaire? (Qu'est-ce que l'urologie) À quoi ressemble votre horarie hebdomadaire? (Qu'est-ce que l'urologie) false bonus 12e9c6ee-fca8-47b0-a106-d4b6e3506a26 Où pensez-vous que l'urologie sera dans dix ans? (Qu'est-ce que l'urologie) Où pensez-vous que l'urologie sera dans dix ans? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/ou-pensez-vous-que-lurologie-sera-dans-dix-ans-quest-ce-que-lurologie-NOlhiFvK Où pensez-vous que l'urologie sera dans dix ans? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Où pensez-vous que l'urologie sera dans dix ans? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:15 Où pensez-vous que l'urologie sera dans dix ans? (Qu'est-ce que l'urologie) Où pensez-vous que l'urologie sera dans dix ans? (Qu'est-ce que l'urologie) false bonus 3ec6ebd1-8e34-43bb-b280-84fff77abc40 Que pensez-vous de l'equilibre entre votre vie professionnelle et votre vie privee? (Qu'est-ce que l'urologie) Que pensez-vous de l'equilibre entre votre vie professionnelle et votre vie privee? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/que-pensez-vous-de-lequilibre-entre-votre-vie-professionnelle-et-votre-vie-privee-quest-ce-que-lurologie-62bOtcC3 Que pensez-vous de l'equilibre entre votre vie professionnelle et votre vie privee? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Que pensez-vous de l'equilibre entre votre vie professionnelle et votre vie privee? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:10 Que pensez-vous de l'equilibre entre votre vie professionnelle et votre vie privee? (Qu'est-ce que l'urologie) Que pensez-vous de l'equilibre entre votre vie professionnelle et votre vie privee? (Qu'est-ce que l'urologie) false bonus d25bc5aa-8975-45a0-beb0-90977869464a Quelle est la meilleure partie d'être un urologue? (Qu'est-ce que l'urologie) Quelle est la meilleure partie d'être un urologue? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/quelle-est-la-meilleure-partie-detre-un-urologue-quest-ce-que-lurologie-Vz__tgcN Quelle est la meilleure partie d'être un urologue? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Quelle est la meilleure partie d'être un urologue? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:40 Quelle est la meilleure partie d'être un urologue? (Qu'est-ce que l'urologie) Quelle est la meilleure partie d'être un urologue? (Qu'est-ce que l'urologie) false bonus bc09501a-0b0d-4f45-8fb9-8ffd6c5eb8bd Quel est le marché du travail pour les urologues de la prochaine décennie? (Qu'est-ce que l'urologie) Quel est le marché du travail pour les urologues de la prochaine décennie? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/quel-est-le-marche-du-travail-pour-les-urologues-de-la-prochaine-decennie-quest-ce-que-lurologie-M4MDPj2K Quel est le marché du travail pour les urologues de la prochaine décennie? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Quel est le marché du travail pour les urologues de la prochaine décennie? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:06 Quel est le marché du travail pour les urologues de la prochaine décennie? (Qu'est-ce que l'urologie) Quel est le marché du travail pour les urologues de la prochaine décennie? (Qu'est-ce que l'urologie) false bonus d8cb5508-497b-4561-8541-b4932849787e Y a-t-il un inconvénient à être urologue? (Qu'est-ce que l'urologie) Y a-t-il un inconvénient à être urologue? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/y-a-t-il-un-inconvenient-a-etre-urologue-quest-ce-que-lurologie-1G3GO4vw Y a-t-il un inconvénient à être urologue? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Y a-t-il un inconvénient à être urologue? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:11 Y a-t-il un inconvénient à être urologue? (Qu'est-ce que l'urologie) Y a-t-il un inconvénient à être urologue? (Qu'est-ce que l'urologie) false bonus 004199e5-1ad9-4b95-9e81-2030e1ad0a67 Quel est votre conseil pour un étudiant intéressé par l'urologie? (Qu'est-ce que l'urologie) Quel est votre conseil pour un étudiant intéressé par l'urologie? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/quel-est-votre-conseil-pour-un-etudiant-interesse-par-lurologie-quest-ce-que-lurologie-042YKxvz Quel est votre conseil pour un étudiant intéressé par l'urologie? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Quel est votre conseil pour un étudiant intéressé par l'urologie? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:49 Quel est votre conseil pour un étudiant intéressé par l'urologie? (Qu'est-ce que l'urologie) Quel est votre conseil pour un étudiant intéressé par l'urologie? (Qu'est-ce que l'urologie) false bonus 4d335ff1-34e5-45c2-9a24-a1ed7dce0c3f Pourquoi avez-vous choisi l'urologie comme spécialité? (Qu'est-ce que l'urologie) Pourquoi avez-vous choisi l'urologie comme spécialité? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Thu, 30 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/pourquoi-avez-vous-choisi-lurologie-comme-specialite-quest-ce-que-lurologie-alrk9sKp Pourquoi avez-vous choisi l'urologie comme spécialité? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Pourquoi avez-vous choisi l'urologie comme spécialité? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:01:46 Pourquoi avez-vous choisi l'urologie comme spécialité? (Qu'est-ce que l'urologie) Pourquoi avez-vous choisi l'urologie comme spécialité? (Qu'est-ce que l'urologie) false bonus 8d940066-4bc2-47f8-8e75-81dc94e40a52 What qualities make a great urologist? (What is Urology Series) What qualities make a great urologist? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Wed, 29 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/what-qualities-make-a-great-urologist-what-is-urology-series-LdYqR70k What qualities make a great urologist? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> What qualities make a great urologist? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:02:20 What qualities make a great urologist? (What is Urology Series) What qualities make a great urologist? (What is Urology Series) false bonus ca1317dc-74b0-4025-b224-196a53a38e37 Why did you pick urology as a specialty? (What is Urology Series) Why did you pick urology as a specialty? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Wed, 29 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/why-did-you-pick-urology-as-a-specialty-what-is-urology-series-zJjZidHE Why did you pick urology as a specialty? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Why did you pick urology as a specialty? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:03:47 Why did you pick urology as a specialty? (What is Urology Series) Why did you pick urology as a specialty? (What is Urology Series) false bonus 6317f5ef-ed5e-491d-b6da-192651f8d100 What is the best part of being an urologist? (What is Urology Series) What is the best part of being an urologist? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Wed, 29 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/what-is-the-best-part-of-being-an-urologist-what-is-urology-series-qOPd0veH What is the best part of being an urologist? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> What is the best part of being an urologist? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:03:48 What is the best part of being an urologist? (What is Urology Series) What is the best part of being an urologist? (What is Urology Series) false bonus a6259830-71bf-4676-809c-1bcc08058f10 Do you find urology a rewarding career? (What is Urology Series) Do you find urology a rewarding career? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Wed, 29 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/do-you-find-urology-a-rewarding-career-what-is-urology-series-aGkeHmnQ Do you find urology a rewarding career? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Do you find urology a rewarding career? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:01:34 Do you find urology a rewarding career? (What is Urology Series) Do you find urology a rewarding career? (What is Urology Series) false bonus 2e189a02-a712-4f7d-967e-08e6c45c1f29 What is urology? (What is Urology Series) What is urology? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Wed, 22 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/what-is-urology-what-is-urology-series-hEnQrsXf What is urology? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> What is urology? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:10:36 What is urology? (What is Urology Series) What is urology? (What is Urology Series) false bonus e9ca8975-cdb4-45a9-a306-20d1504874df Qu'est-ce que l'urologie? (Qu'est-ce que l'urologie) Qu'est-ce que l'urologie? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Mon, 13 Jul 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/quest-ce-que-lurologie-quest-ce-que-lurologie-Ump7JEGC Qu'est-ce que l'urologie? (Qu'est-ce que l'urologie). To view the accompanying video of this audio clip please click here.

]]> Qu'est-ce que l'urologie? (Qu'est-ce que l'urologie) Canadian Urological Association / L'Association des urologues du Canada 00:10:57 Qu'est-ce que l'urologie? (Qu'est-ce que l'urologie) Qu'est-ce que l'urologie? (Qu'est-ce que l'urologie) false bonus beed0011-a7f2-41cb-9c3e-4216dde21b22 What is your weekly schedule like? (What is Urology Series) What is your weekly schedule like? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Tue, 14 Apr 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/what-is-your-weekly-schedule-like-what-is-urology-series-cW2cLH0E What is your weekly schedule like? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> What is your weekly schedule like? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:01:03 What is your weekly schedule like? (What is Urology Series) What is your weekly schedule like? (What is Urology Series) false bonus 528fcf4e-04b8-4573-bc74-984291d5d0d2 Is there a downside to being an urologist? (What is Urology Series) Is there a downside to being an urologist? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Tue, 14 Apr 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/is-there-a-downside-to-being-an-urologist-what-is-urology-series-Ye0rVtRX Is there a downside to being an urologist? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Is there a downside to being an urologist? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:02:07 Is there a downside to being an urologist? (What is Urology Series) Is there a downside to being an urologist? (What is Urology Series) false bonus 974fa6be-7285-4d4c-924f-85c405bc4464 What is the job market for urologists in the next decade? (What is Urology Series) What is the job market for urologists in the next decade? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Tue, 14 Apr 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/what-is-the-job-market-for-urologists-in-the-next-decade-what-is-urology-series-yf4IERni What is the job market for urologists in the next decade? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> What is the job market for urologists in the next decade? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:01:24 What is the job market for urologists in the next decade? (What is Urology Series) What is the job market for urologists in the next decade? (What is Urology Series) false bonus 7ca78758-807e-435b-85bb-030334130c77 How do you feel about your work life balance? (What is Urology Series) How do you feel about your work life balance? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Tue, 14 Apr 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/how-do-you-feel-about-your-work-life-balance-what-is-urology-series-IQEy_Jnd How do you feel about your work life balance? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> How do you feel about your work life balance? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:02:15 How do you feel about your work life balance? (What is Urology Series) How do you feel about your work life balance? (What is Urology Series) false bonus b07782d4-2f1d-46a4-8d70-9493914c63cb Where do you think urology will be in ten years from now? (What is Urology Series) Where do you think urology will be in ten years from now? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Tue, 14 Apr 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/where-do-you-think-urology-will-be-in-ten-years-from-now-what-is-urology-series-_A5wY3cP Where do you think urology will be in ten years from now? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Where do you think urology will be in ten years from now? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:02:47 Where do you think urology will be in ten years from now? (What is Urology Series) Where do you think urology will be in ten years from now? (What is Urology Series) false bonus e86cf2ec-a447-41d9-aeea-4bb314756f8c What makes urology special? (What is Urology Series) What makes urology special? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Tue, 14 Apr 2020 04:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/what-makes-urology-special-what-is-urology-series-PFkjiWCl What makes urology special? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> What makes urology special? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:02:23 What makes urology special? (What is Urology Series) What makes urology special? (What is Urology Series) false bonus bc812817-d362-44c4-ab1f-4201e5c66185 What is your advice for a student interested in urology? (What is Urology Series) What is your advice for a student interested in urology? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> Sat, 8 Feb 2020 05:00:00 +0000 corporate.office@cua.org (Canadian Urological Association / L'Association des urologues du Canada) https://cua.simplecast.com/episodes/what-is-your-advice-for-a-student-interested-in-urology-what-is-urology-series-Olp3Pp98 What is your advice for a student interested in urology? (What is Urology Series). To view the accompanying video of this audio clip please click here.

]]> What is your advice for a student interested in urology? (What is Urology Series) Canadian Urological Association / L'Association des urologues du Canada 00:02:43 What is your advice for a student interested in urology? (What is Urology Series) What is your advice for a student interested in urology? (What is Urology Series) false bonus